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CHAPTER I 
 
INTRODUCTION 
 
Cyclooxygenase-2 
 
 The cyclooxygenase enzymes, COX-1 and COX-2, catalyze the rate-limiting 
steps in the biosynthesis of prostaglandins and thromboxanes, collectively known as 
prostanoids. The cyclooxygenases utilize arachidonic acid (AA) as their substrate and 
convert it to prostaglandin H2 (PGH2) (Figure 1). AA is generated by phospholipase A2 
and is further oxidized by COX. The downstream isomerases can convert PGH2 to 
prostacycline, prostaglandins, or thromboxane A2, which play a vital role in multiple 
physiologic and pathologic processes (2). 
 
COX-2 was originally cloned as a primary response gene whose messenger RNA 
was rapidly induced by treatment with phorbol esters (3). Regulation of expression of 
COX-1 and COX-2 is distinct: COX-1 is constitutively expressed and responsible for 
“housekeeping” prostaglandin synthesis, whereas COX-2 is an inducible enzyme whose 
expression and activity in most cells are upregulated in response to a variety of 
proinflammatory stimuli (2, 4, 5).  Various extracellular stimuli including growth factors, 
cytokines and tumor promoters can also induce COX-2 expression.  
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      Figure 1.  Synthesis of prostanoids by cyclooxygenases. 
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COX-2 and cancer 
 A substantial body of research has attributed an important role for COX-2 and its 
products in cancer development, cancer cell growth and cancer cell survival.  Increased 
amounts of COX-2 are commonly found in both premalignant tissues and malignant 
tumors.  This appears to reflect the effects of oncogenes, growth factors and tumor 
promoters, known inducers of COX-2 (6, 7).  The most specific data supporting the 
cause-effect relation between overexpression of COX-2 and carcinogenesis come from 
genetic studies in mice (8, 9). It also has been demonstrated that prostaglandins and other 
COX-2-generated downstream mediators promote tumor cell proliferation and survival in 
an autocrine and/or paracrine manner (10-14).  Furthermore, knockout of the COX-2 
gene suppressed tumorigenesis in mice with a genetic predisposition for polyp formation 
(8).  
 
Pharmacological evidence also implicates COX-2 in tumorigenesis.  Selective 
inhibitors of COX-2 can reduce the formation of intestinal, breast, lung, skin, bladder, 
and tongue tumors in rodents (8, 15-22).  Nonsteroidal anti-inflammatory drugs 
(NSAIDs) have also been implicated to have COX-independent mechanisms of inhibiting 
tumorigenesis (23).  However the concentrations used in these studies were so high the 
pharmacological relevance is questionable.  Collectively the genetic and pharmacological 
evidence strongly suggests COX-2 is a potential therapeutic target for preventing cancer. 
 
 
 
 4
NSAIDs and colorectal cancer 
Colorectal cancer (CRC) is highly prevalent in the western world where it is the 
second most frequent cause of cancer-related death. In 2007, an estimated 153,760 cases 
of colorectal cancer will be diagnosed, and 52,180 people will die from the disease (24).  
By the age of 70 about 50% of the western population develops an adenomatous polyp 
and approximately 10% of these polyps will progress to malignancy (25).  CRC is a 
multi-factorial disease.  It is a result of a time dependent accumulation of mutations in 
genes controlling colonic epithelial cell turnover, and its incidence depends on both 
genetic as well as environmental risk factors, such as diet and lifestyle behavior. It is 
therefore not surprising to find various differences in prevalence, age of onset and 
anatomical distribution among various international populations and intra-national ethnic 
groups. 
 
From a molecular-genetic perspective CRC is likely the best understood solid 
malignancy, which relates to the accessibility of the tumors and the fact that different 
stages of the same malignancy can coexist within the same patient.  The seminal 
adenoma-carcinoma sequence of tumor progression integrates the notions that colorectal 
tumors result from mutational activation of oncogenes combined with inactivation of 
tumor-suppressor genes, multiple gene mutations are required to produce malignancies 
and that genetic alterations may occur in a definite sequence and yet the accumulation 
rather than the chronological order of these changes determines the histopathological 
characteristics of the colorectal tumor (26). While there is a 90% 5-year survival rate with 
surgical resection and/or adjuvant therapy of early CRC, only 37% of CRC are diagnosed 
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at this early stage. In advanced CRC traditional chemotherapy regimens have provided 
only a modest improvement in 5-year survival rates (27).  For this reason, in addition to 
improved therapeutic options, better cancer prevention strategies must be developed. 
 
Beginning with Waddell’s serendipitous finding that sulindac, an NSAID used to 
treat a desmoid tumor also caused the dramatic regression of rectal polyps (28), a number 
of studies have shown that regular use of NSAIDs over a 10–15-year period can reduce 
the relative risk of developing CRC by 40%–50% (29-31). Although these studies were 
originally developed and substantiated in rodent models (32, 33), subsequent clinical 
trials confirmed that NSAID use leads to the regression of preexisting adenomas in 
patients with familial adenomatous polyposis (FAP) (28, 34-37).   
 
In 1994 Eberhart and colleagues were the first to show a positive relationship 
between COX-2 expression and human CRC (38).  Since then subsequent reports have 
confirmed COX-2 is overexpressed in about 90% of colorectal adenocarcinomas and in 
40–90% of colorectal adenomas (39-41).  In adenomas, COX-2 expression correlates 
with size and seems to be unrelated to the degree of dysplasia (38, 42, 43).  COX-2 
expression is thus observed early during colorectal tumor development in both benign 
and malignant tumors; however, these studies do not confirm COX-2 overexpression to 
be a central event.  Direct evidence that links COX-2 to colorectal tumor development 
was obtained using animal models: chemically-induced and genetically engineered 
animal models of intestinal polyposis.  Elevated COX-2 expression is observed in colonic 
adenomas and carcinomas from multiple intestinal neoplasia (Min) mice, which harbor a 
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mutation in the APC gene, and azoxymethane (AOM)-treated rats (44, 45). Deletion of 
COX-2 in two Min mice models decreased tumor formation (8, 46). Nonselective 
NSAIDs and COX-2 selective inhibitors had chemopreventive effects in AOM-treated 
rats (16, 47-50) and reduced the number of intestinal polyps in Min mice (15, 17, 51-54). 
Collectively, these studies suggest COX-2 is a biologic target of NSAIDs in vivo and 
selective COX-2 inhibitors may be efficacious in the prevention and treatment of CRC.  
Interestingly COX-1 deletion in Min mice also decreased polyp number (46) suggesting 
the actual enzymatic source may not be as important as the overall load of prostaglandins. 
 
In 1971 Vane identified prostaglandins to be the target of NSAID activity (55). 
NSAIDs are thought to exert their anti-inflammatory, analgesic and anti-pyretic effects 
mainly by inhibiting the biosynthesis of prostaglandins (Figure 1) (55). Prostaglandins 
are members of a large family of bioactive lipid molecules known as eicosanoids.  In 
humans, prostaglandins are involved in diverse functions including blood clotting, 
ovulation, initiation of labor, bone metabolism, nerve growth and development, wound 
healing, kidney function, blood vessel tone and immune responses (56). Given the broad 
role these bioactive compounds play in normal human physiology, it is not surprising that 
systemic suppression by NSAIDs can lead to unwanted side effects.  These side effects 
increase with the age of the population and result in an increased risk of gastrointestinal 
bleeding, even at relatively low doses.  Enormous effort has been expended to develop 
NSAIDs whose specificity of action will enhance the benefits of eicosanoid inhibition yet 
minimize the harmful effects. 
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Prostaglandins 
Prostaglandins, thromboxanes and leukotrienes, collectively referred to as 
‘eicosanoids’, are the metabolites of AA (Figure 1). Discovery of eicosanoids (from 
Greek eicosa=twenty; for twenty carbon fatty acid derivatives), was initiated in 1930 (57-
59). First, it was found that exclusion of fat from the diet of rats led to growth retardation, 
reproductive disturbances, scaly skin, kidney lesions and excessive water consumption, 
which led to the discovery of essential fatty acids. Second, a factor with fatty acid 
properties and vasodepressor and smooth muscle-stimulating activity was identified and 
termed "prostaglandin." Bergström and Samuelsson linked these observations when they 
elucidated the structures of the "classical" prostaglandins and demonstrated that they 
were produced from an essential fatty acid, AA (60). 
 
Prostaglandins are produced in most cells in the body and act as autocrine and 
paracrine mediators of such cell functions as pain generation, vascular permeability, 
febrile response and uterine contractility (61).  The chemistry of eicosanoid biosynthesis 
is well known. Most eicosanoids are derived from AA that is sequestered in membrane 
phospholipids.  Upon physiologic and pathologic stimulation, the rate-limiting step of 
prostanoid synthesis is the release of AA from the plasma membrane by phospholipase 
A2.  Thereafter, AA is metabolized through 1 of 3 major pathways:  the cyclooxygenase 
pathway, the lipoxygenase pathway or the cytochrome P-450 monooxygenase pathway, 
depending on the availability of enzymes.  Prostaglandin H synthase, commonly referred 
to as cyclooxygenase (COX), as mentioned earlier, is the key regulatory enzyme which 
catalyzes the conversion of AA to PGG2 and PGH2.  PGH2 is subsequently converted by 
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cell-specific synthases to a variety of eicosanoids that include PGE2, PGD2, PGF2α, PGI2 
and thromboxane A2 (TXA2) (Figure 1).   
 
Prostaglandins can signal at or immediately adjacent to their site of synthesis. 
They are not only key mediators of inflammation and involved in apoptosis, cell 
differentiation and oncogenesis, but also play critical physiologic roles in tissue 
homeostasis and function. For example, gastric mucosal protective function, sleep 
induction and vascular smooth muscles contraction and relaxation are all dependent upon 
these compounds (61-63).  Some actions of prostaglandins are illustrated in Figure 2.  
 
Biological functions of PGE2 
Among the prostanoids, prostaglandin E
2 
(PGE
2
) is the most widely produced in 
the body, the most widely found in animal species and exhibits the most versatile actions 
(64).  PGE2 activates a pleiotropic effect on signal transduction and the actual cellular 
effects exerted depend on the receptor subtypes expressed. PGE2 is a major COX product 
in a number of physiological settings. It was first isolated and its structure determined in 
the 1960s (65). Thereafter, this prostaglandin was found in many different tissues.  PGE
2 
plays a protective role in maintaining the integrity of the gastric mucosa (66).  The 
production of PGE
2 
in the kidney is critical for normal renal function by preserving renal 
blood flow and glomerular filtration rate in settings of physiological stress, modulating 
salt and water transport in the distal tubule, and stimulating renin release from the 
juxtaglomerular apparatus (67).  PGE
2 
was also shown to play a role in the maintenance 
of blood pressure, particularly in the setting of salt overload (68). In certain instances, 
 9
 
Figure 2.  Prostaglandin actions and synthesis. Mechanical trauma, cytokines, growth factors, 
or various inflammatory stimuli activate cells, triggering signalling, including cytosolic 
phospholipase (cPLA2) translocation to endoplasmatic reticulum and nuclear membranes, release 
of arachidonic acid from membrane lipids and production of PGH2 intermediate by COX-2 or 
COX-1. Heterogeneous family of PGH2 metabolizing enzymes can form PGE2, PGD2, PGF2α, 
PGI2 (prostacyclin) and TxA2 (thromboxane). These prostaglandins may pass cell through a 
known prostaglandin transporter (PGT) to exert their actions on a family of prostaglandin 
receptors named EP1, EP2, EP3, EP4, DP1, DP2, FP, IP, TPα and TPβ. Adapted from (61). 
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PGE
2 
was observed to have multiple and apparently opposing functional effects. For 
example, PGE
2 
elicits both smooth muscle relaxation and constriction (69, 70). 
Complexity was also observed in modulation of the immune response by PGE
2
; it was 
shown that PGE
2 
regulates the function of many cell types including macrophages, 
dendritic cells, T and B lymphocytes leading to both pro- and anti-inflammatory effects 
(71). PGE
2 
signalling promotes tumor angiogenesis (72), increases cell proliferation and 
stimulates oncogenesis (73).  
 
PGE2 and cancer 
COX-2-derived PGE2 is a pro-inflammatory bioactive lipid and the major 
prostaglandin produced in many human solid tumors (74-76).  Among the various 
downstream prostaglandins, PGE2 has long been suggested as the key player. TxA2, 
which has been shown to promote angiogenesis,  is the only other prostaglandin 
implicated in oncogenesis (77).  PGE2 mediates essential roles in tumor progression, such 
as tumor cell proliferation, invasion, angiogenesis, and immunosuppression.  The 
stimulatory effect of PGE2 was first observed in dog kidney cells.  These cells required 
PGE2 or PGE1 for growth in serum-free media (78, 79).  Several studies since have 
provided direct evidence in regards to the role of PGE2 in promoting tumor growth.  For 
example, PGE2 was shown to reverse NSAID-induced adenoma regression (80) and 
accelerate intestinal adenoma growth in Min mice (81).   
 
While COX-2 selective NSAIDs are thought to inhibit all COX-2-mediated 
prostaglandin production, it is predominantly PGE2 that is thought to be responsible for  
11 
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Figure 3. Signal transduction of prostaglandin E2 receptors.  PGE2 is actively transported out of the 
cell, where it exerts its effect by binding to its seven transmembrane G-protein coupled receptors, EP1, 
EP2, EP3 and EP4 to activate second messengers, such as cAMP and inositol (1,4,5)-trisphosphate (IP3), 
and intracellular signalling cascades. 
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promoting colorectal tumorigenesis, with elevated levels reported in benign and 
malignant human and rodent colorectal tumors in vivo (74, 82, 83).  There is a body of 
evidence, beyond the association of a cancer phenotype and increased levels of PGE2, 
which suggests that PGE2 also contributes to the development and progression of 
colorectal cancer. The level of PGE2 increases in a size-dependent manner in colorectal 
adenomas from FAP patients (84).  PGE2 can induce angiogenesis in vitro and increases 
cellular resistance to apoptosis (85), enhancing the survival and motility (86, 87) in colon 
cancer. Immune surveillance is also inhibited by PGE2 (88).  Cumulative evidence 
indicated that COX-2-derived PGE2 provides growth advantage to colorectal carcinomas 
through transactivation of the epidermal growth factor receptor (EGFR) signalling system 
(73, 87).  Furthermore, PGE2 exposure induces the expression of VEGF (vascular 
endothelial growth factor) in colon cancer cells (89). Studies with experimental animals 
also suggest that PGE2 promotes tumorigenesis.  For instance, treatment with an anti-
PGE2 monoclonal antibody retards the growth of a transplantable tumor in vivo (90).   
 
The side effects associated with long term COX-2 inhibition are predominantly 
due to the fact that as well as inhibiting the production and signalling of pro-tumorigenic 
PGE2, all inducible prostaglandin and thromboxane production is inhibited. So while 
blocking PGE2 synthesis along with all other prostanoids with NSAIDs confers a 
protective effect, inactivating PGE2 via its catabolism by prostaglandin dehydrogenase 
(PGDH) provides a promising COX-2 independent method of targeting PGE2 in order to 
inhibit cancer progression.  The steady-state cellular levels of PGE2 depend on the 
relative rate of synthesis by COX-2/PGE synthases and its degradation by PGDH.  
13 
Genetic deletion of PGDH in mice leads to increased tissue levels of PGE2 (91).  Loss of 
PGDH expression correlates with tumor formation in several types of cancers (92-95).  
When a subset of colorectal carcinomas were analyzed, PGDH was observed down-
regulated (92) and further studies showed EGF is responsible for repressing PGDH by 
inducing the transcriptional repressor Snail, which binds to the PGDH promoter (96).  
Interestingly, NSAIDs have been shown to upregulate PGDH expression in colorectal 
cancer (92).  Collectively, these studies suggest that by decreasing PGE2 levels, PGDH 
serves a novel tumor suppressive role due to the loss of expression during tumor 
progression. 
 
EP receptors 
The diverse effects of PGE2 on various tissues suggested the existence of multiple 
transmembrane receptor subtypes, which was confirmed by molecular cloning.  These 
receptors were named EP1, EP2, EP3, and EP4, which are all products of separate genes 
and yet highly conserved among mammalian species (97).  For example, the sequence 
homology between human and mouse orthologues for the EP1, EP3 and EP4 is 84%, 
84% and 88%, respectively (98). Although the four cloned EP receptor subtypes bind 
PGE2 with higher affinity than other prostanoids, they are not closely related when 
compared to other prostanoid receptors based on amino acid homology. Moreover, 
stimulation by PGE2 leads to activation of different G-proteins leading to various 
intracellular signal transduction pathways depending of the EP receptor subtype engaged 
(Figure 3). Synthesized PGE
2 
can be released through a prostaglandin transporter (PGT) 
(99) out of the cell and then bind to receptors in the vicinity of the site of PGE
2 
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production. Of the four known EP receptors, EP3 and EP4 receptors bind PGE
2 
with the 
highest affinity (K
d 
~ 1 nM), whereas EP1 and EP2 receptors bind with lower affinity (K
d 
> 10 nM) (100). The EP1 receptor mediates PGE
2
-induced elevation of free Ca2+
 
concentration, whereas the EP2 and EP4 receptors are coupled to Gs G-protein and their 
activation leads to an increase in cyclic AMP (cAMP) levels. The signalling pathway of 
the EP3 receptor mediates inhibition of adenylate cyclase via Gi (Figure 3) (98).  
 
Most prostanoid receptors are G protein–coupled rhodopsin-type receptors with 
seven transmembrane domains, and each is encoded by different genes. In addition, there 
are several splice variants of the EP3 receptor, which differ only in their intracellular C-
terminal tails. Prostanoid receptors are generally expressed on the cell surface plasma 
membrane; although recent data suggests some EP receptor subtypes are also associated 
with the nuclear membrane (101, 102). In particular, endogenous EP1 receptor has been 
shown to have perinuclear localization in porcine cerebral microvascular endothelial 
cells, as well as cloned EP1 in Swiss 3T3 fibroblasts (101). EP3 and EP4 have also been 
suggested to be functionally expressed in the nuclear membranes of neonatal porcine 
brain and adult rat liver cells (102).  Among the four subtypes EP2 and EP4 receptors 
mediate a cAMP rise and have been termed "relaxant" receptors, whereas the EP1 
receptor induces calcium mobilization and constitutes as a "contractile" receptor. The 
remaining receptor, EP3, induces a decline in cAMP levels and has been termed the 
"inhibitory" receptor (Figure 3). However, these basic classifications do not always apply 
as the G-protein activated by a specific receptor may differ between cell types. For 
instance, various Gs-coupled EP receptors may activate Gq in specific cell types.   
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In the 1990s the functional cDNAs for each EP subtype was isolated and 
expression of recombinant receptors in mammalian cells allowed for the characterization 
of their structural and biochemical properties (103-106). In addition, the tissue and cell 
distribution of the receptor subtypes was studied and correlated with pharmacological 
studies using COX inhibitors and various PGE2 analogs having agonistic and antagonistic 
effects allowing us to define the actions of each subtype.  Lastly, targeted disruption of 
the EP receptor genes has enabled us to examine the physiological and 
pathophysiological importance of the action of PGE2 mediated by each EP receptor.  
 
Structure of EP receptors 
The EP receptor subtypes have seven hydrophobic putative transmembrane 
domains, and thus belong to a rhodopsin-type receptor superfamily.  Although the four 
EP receptor subtypes respond to PGE2, the amino acid homology among EPs is quite 
limited making it difficult to use sequence comparison among subtypes in order to learn 
about ligand binding specificity from simply comparing amino acid sequences (Figure 
4).  The mouse EP1, EP2, EP3 and EP4 consist of 405, 362, 366 and 513 amino acids, 
respectively.  The homology of EP1 to EP2, EP3 and EP4 is 30, 33 and 28%, 
respectively.  Even between the two adenylate cyclase-stimulatory subtypes, EP2 and 
EP4, the amino acid identity is only 31%.  The EP2 receptor shares more homology to the 
other two relaxant receptors IP (40%) and DP (44%) than any other EP.  Similarly, the 
EP1 is more homologous to the other two contractile types of prostanoid receptors, TP 
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Figure 4. Amino acid sequence alignment for mouse EP receptor subtypes and EP3 variants.  Amino 
acid identities are indicated by shading; predicted transmembrane domains are shown with overlining and 
gaps are indicated with dashes (64). 
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(34%) and FP (35%).  The limited homology shared among EPs probably reflects the 
phylogenetic relationship among prostanoid receptors (64, 107). 
 
Structurally, the EP4 receptor subtype has the longest intracellular C-terminal tail 
and a long intracellular third loop. The EP1 receptor subtype also has a long third loop 
while the EP2 and EP3 receptor subtypes have more compact structures.  The EP3 
receptor is unique from other EP receptors in that it exists as multiple variants generated 
by alternative splicing.  These variants differ only in the carboxy-terminal tails and are 
capable of inducing a broad range of effects.  These variants show similar ligand binding 
properties but activate different signal transduction pathways further described below. 
 
Properties of EP receptors 
Each of the four subtypes of EP receptors display a selective ligand-binding 
specificity that distinguishes it from one another.  In fact, each was identified by their 
preferential responsiveness to native ligand and subsequently to synthetic PGE2 analogs 
synthesized to selectively mimic or inhibit specific effects.  For instance, using select 
regions of the GI tract from farm animals, the EP receptors were first characterized since 
PGE2 had the most potent agonistic effect of all prostanoids (108). They were then 
further subdivided by their sensitivity to anatagonists, for instance EP1 to SC-19220, and 
EP2 from EP3 on the basis of its different sensitivities to 11-deoxy-PGE0 and sulprostone 
(109).  Lastly, EP4 was first discovered to have relaxant effects on smooth muscle like 
EP2 however it differed from EP2 as it displayed weak potency to AH13205 and its 
antagonism by AH23848 (110).  These studies while only qualitative have proven to be 
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both valid and successful at characterizing the EP receptor subtypes.  Bioassay tissues 
however have several receptor types and therefore the outcome observed by each 
compound tested demonstrates the sum total effect of all receptors present in the tissue. 
Important to note were the differences in the degree of responsiveness and the efficacy of 
actions in different tissues and species.    
 
Cloning of the EP subtypes has allowed homogeneous expression of each subtype 
from the same species to be evaluated for ligand-binding properties, signal transduction 
properties as well as the cross-reactivity of compounds for several types of receptors.  
The cDNA for the mouse EP1 receptor was isolated from the mouse kidney library (106), 
and its human homologue was subsequently isolated from a human erythroleukemia cell 
(111).  Although sulprostone was first identified as a potent EP1 receptor agonist, it is 
more potent as an EP3 agonist (112). To date, there is one reported example of a highly 
selective EP1 receptor agonist, ONO-D1-004.  Well-known antagonists for the EP1 
receptors are SC-19220 and AH6809 (110).   
 
Initially two cloned EP receptor subtypes, positively coupled to adenylate cyclase, 
were reported as EP2 (103, 113).  The EP2 receptor is pharmacologically defined as 
being sensitive to butaprost. Butaprost is highly selective for this receptor as it only 
shows affinity to EP2.  Later on, it was shown that the first EP2 subtype cloned was 
actually EP4 and the latter represents the EP2 subtype.  The EP2 subtype can be 
distinguished from EP4 by its insensitivity to the EP4 agonist PGE1-OH and insensitivity 
to the weak EP4 antagonist AH23848.  Furthermore, the EP4 receptor undergoes rapid 
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desensitization after agonist stimulation, whereas EP2 does not (Table 1).  The mouse 
EP3 receptor binds to the following EP ligands with an order of affinity of sulprostone, 
MB28767, PGE2 PGE1-OH, 11-deoxy-PGE1, GR63799X, 16,16-dimethyl-PGE2, 17-
pheynyl-PGE2 > misoprostol (98).  Although EP ligands such as sulprostone and 
MB28767 bind other receptors, they show the highest affinities for the EP3 receptor.  
GR63799X, on the other hand, has a very high affinity to only the EP3 receptor subtype 
indicating it is a highly selective agonist for this receptor.  Interestingly, although 
sulprostone and PGE2 show equal potency for EP3-Gi activation, sulprostone potency to 
EP3-Gs is 10 times weaker than PGE2.  Since sulprostone demonstrates a lower affinity to 
Gs coupled EP3 compared to Gi suggests the ligand-binding properties of prostanoid 
receptors can depend on the G-protein coupled to the receptor.  
 
PGE2 can cause the stimulation or suppression of neurotransmitter release, the 
inhibition or stimulation of sodium and water reabsorption in the kidneys; these opposite 
actions of PGE2 are due to the receptor subtypes being coupled to a variety of signal 
transduction pathways (Table 1).  Activation of the human EP1 receptor is most likely 
mediated by Gq activation and leads to IP3 generation and increased intracellular calcium. 
Narumiya et. al. suggests however that the increase is not Gq mediated since agonist 
stimulation in the mouse EP1 causes a strong increase in calcium but only a modest 
increase in IP3 (106).  The EP2 receptor subtype activates Gs, which in turn stimulates 
adenylate cyclase and leads to the production of the second messenger cyclic AMP 
(cAMP) (114) and thus activation of the cAMP-dependent protein kinase termed PKA.  
Although EP2 and EP4 couple to increases in cAMP and in some processes function 
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redundantly, there are processes in which EP2 and EP4 play distinct roles. For instance, 
EP4 selectively couples to PI3K and subsequently activates extracellular signal-regulated 
kinases (ERK) 1 and 2 (115, 116).  The EP3 receptor was originally identified as a 
smooth muscle constrictor (110) and multiple spliced variants exist defined by their 
unique C-terminal tails.  Multiple spice variants may explain the differences in receptor 
phosphorylation, receptor desensitization and variations in signal transduction pathways 
activated by the EP3 receptor.  While EP2 and EP4 stimulate adenylate cyclase and 
generate cAMP, the EP3 receptor generally inhibits cAMP production via activation of 
the pertussis-toxin sensitive G-protein Gi (117).  It is important to note however that 
splice variants have been described to couple to different signalling pathways.  For 
instance, the EP3 receptor has been shown to signal through the small GTP-binding 
protein Rho to induce neurite retraction via a tyrphostin A25-sensitive tyrosine kinase 
upstream of Rho (118) and the p160 RhoA-binding kinase ROKα downstream of Rho 
(119) as well as induce stress fiber formation in MDCK cells via Rho (120). 
Next, besides differences in actions dependent on the G-proteins to which they are 
coupled to, the EP receptor subtypes may also vary with respect to the tissue distribution 
of their expression. 
 
Distribution of EP receptors 
Northern blot and in situ hybridization analyses have revealed detailed 
information on the EP subtype distribution in the body and the levels of expression 
among tissues.  The majority of studies on EP receptors have investigated expression at 
the mRNA level by reverse transcription-PCR (RT-PCR) or in situ hybridization due to  
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TABLE 1.  
Subtype Variant 
Amino 
Acid Gprotein Signaling Desensitization Constitutive activity 
EP2  362 Gs cAMP↑ No   
EP4  513 Gs cAMP↑, PI3K Yes   
EP1  405 Gq ? Ca2+↑ -   
EP3 EP3α 366 Gi, G12 cAMP↓, IP3/Ca2+↑, Rho Yes  ++ 
  EP3β 363 Gi, G12 cAMP↓, IP3/Ca2+↑, Rho No  - 
  EP3γ 365 Gi, Gs 
cAMP↓, cAMP↑ 
IP3/Ca2+↑, Rho -  + 
 
Signal transduction properties of EP receptor subtypes and EP3 variants. Data obtained from mouse 
EP subtypes are summarized, and representative signal transduction pathways for each receptor are shown. 
PI3K, phosphatidylinositol 3-kinase;  ↑, increase;  ↓, decrease (64). 
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the lack of well-characterized antibodies to EP receptors.  Among the prostanoid 
receptors, EP3 and EP4 receptors are the most widely distributed throughout the body. In 
contrast, the distribution of EP1 is restricted to several organs, such as the kidney, lung, 
and stomach, and EP2 is the least abundant of the EP receptor subtypes.  EP1 receptors 
mediate the contraction of smooth muscle in various tissues including the gastrointestinal 
tract, respiratory tract, vas deferens, myometrium and iris sphincter muscle.  EP1 receptor 
mRNA is expressed most highly in the kidney, followed by gastric muscularis mucosae 
and then adrenal tissue (121).  The precise tissue distribution of the EP2 receptor has 
been revealed to be most abundant in the uterus and only low levels of expression in the 
kidney (121).  Although EP2 mRNA is the least abundant among the EP receptor 
subtypes, it is effectively induced in response to stimuli and does not undergo 
desensitization.  EP4 receptor mRNA is highly expressed compared to the EP2 receptor 
and widely distributed in such organs as the thymus, ileum, lung, spleen, adrenal, and 
kidneys (122).  EP4 receptor activation has been shown in venous and arterial beds to 
have important vasodilator effects (110).  When examined in the mouse gastrointestinal 
tract, EP4 mRNA is highly expressed in the gland of the gastric antrum suggesting this 
subtype is involved in PGE2-mediated mucus secretion.  Additionally, EP4 is found in 
epithelial cells of the intestinal villi (123) and since EP4 increases cAMP and PGE2 
stimulates chloride secretion and inhibits salt absorption via production of cAMP, the 
above findings suggest that EP4 is involved in these processes and consequently PGE2-
induced diarrhea (124).  Nuclease protection and northern analysis demonstrated 
relatively high levels of EP3 receptor expression in several tissues including kidney, 
uterus, adrenal gland, and stomach tissues.  EP3 mRNA was most abundantly expressed 
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in the brain and is widely distributed over the central nervous system (125).  In the mouse 
gastrointestinal tract EP3 mRNA is expressed in smooth muscle cells in the longitudinal 
but not circular muscle layer as well as enteric nervous system indicating it may regulate 
smooth muscle contraction both directly and indirectly (123).  In addition, the expression 
of EP3 mRNA was also found in fundic gland epithelial cells, both parietal and chief 
cells, suggesting its involvement in acid secretion.   
 
Genetic deletion of the EP receptors 
Understanding of the pharmacology and physiologic roles of each of the EP receptors 
has been enhanced greatly by derivation of individual EP receptor "knockout" mouse models 
(Table 2).  Experiments using EP1 deficient mice showed PGE2 acts through EP1 to control 
impulsive behavior under stress (126), a finding potentially exploitable for development of 
drugs that attenuate impulsive behavior in humans.  Recently the role of the EP1 receptor in 
modulating urine concentrations was investigated since it is expressed along the renal 
collecting duct where arginine-vasopressin (AVP) exerts its anti-diuretic activity and in the 
paraventricular and supraoptic nuclei of the hypothalamus where AVP is synthesized.  Data 
suggests that PGE2 modulates urine concentration by acting on EP1 receptors, not in the 
collecting duct, but within the hypothalamus to promote AVP synthesis in response to acute 
water deprivation (127).  The EP1 receptor has also been shown to play a direct role in 
mediating algesia and in regulating blood pressure (128).  Systolic blood pressure is 
significantly reduced in EP1 receptor–deficient mice and is accompanied by increased renin-
angiotensin activity suggesting a role for this receptor in cardiovascular homeostasis. 
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Functional studies suggest the EP2 receptor plays an important role in uterine 
implantation (68, 129) and a relaxant role in bronchioles and the vasculature. In addition, 
recent studies have demonstrated that targeted disruption of the EP2 receptor interferes with 
fertility and results in salt-sensitive hypertension (68, 129, 130). For instance, upon PGE2 or 
butaprost administration intravenously, only wildtype but not EP2 -/- mice became 
hypotensive.  Surprisingly, EP2 -/- mice became hypertensive with PGE2 indicating the 
absence of EP2 abolishes the ability of the vasculature to dilate in response to PGE2 and 
unmasks the contractile response via vasoconstrictor EP receptor(s) (68).  In addition, PGE2-
EP2 signaling is also reported to contribute to the spinal inflammatory hyperalgesia in the 
zymosan A peripheral inflammation model (131).  Yeast extract injected subcutaneously 
into the paw induces inflammatory hyperalgesia. Although thermal and mechanical 
sensitization in EP2 -/- mice is similar to wildtype mice at 2 hours post injection, from 4 
hours onward EP2 -/- mice recovered faster from hyperalgesia. These results suggest a 
dominant role for PGE2-EP2 signaling in the generation of inflammatory pain.  COX-2 
deficient mice have been shown to have reproductive failures in early pregnancy such as in 
ovulation, fertilization, implantation, etc. suggesting that prostaglandins play a crucial role.  
Kennedy et. al. found EP2 -/-  female mice have consistently fewer pups than wildtype and 
detected slightly impaired ovulation and a reduction in fertilization concluding the failure in 
COX-2 deficient mice is due to dysfunction of the EP2 receptor (68).  Whether 
polymorphisms in the EP2 receptor are associated with infertility and/or hypertension in 
humans remains to be determined. 
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TABLE 2 
Genotypes Phenotypes 
EP1 (−/−)  Defect in concentrating urine 
EP2 (−/−)  Impaired ovulation and fertilization 
 Salt-sensitive hypertension 
 
Faster recovery from hyperalgesia 
Vasopressor or impaired vasodepressor response to intravenous 
PGE2 
 Loss of bronchodilation with PGE2 
 Impaired osteoclastogenesis in vitro 
EP3 (−/−)  Impaired febrile response to pyrogens 
 Impaired duodenal bicarbonate secretion and mucosal integrity 
 Enhanced vasodepressor response to intravenous infusion of PGE2 
 Disappearance of indomethacin-sensitive urine diluting function 
EP4 (−/−)  Patent ductus arteriosus 
 Impaired vasodepressor response to intravenous infusion of PGE2 
 Decreased inflammation-dependent bone resorption 
 
Major phenotypes of EP receptor knockout mice (132). 
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PGE2 is known to have bone-resorptive activity and to mediate bone resorption 
induced by cytokines and LPS.  Several groups found impaired osteoclast formation in 
cells cultured from EP2- and EP4-deficient mice (133-135). This likely reflects the 
redundant roles of the two relaxant EP receptor subtypes.  In addition to inducing bone 
resorption, exogenous PGE2 can also induce bone formation, although the receptor 
mediating this latter response has not been identified. 
 
Mice with targeted disruption of the EP4 receptor gene have shown EP4 to play a 
particular role in regulating the peri-natal closure of the pulmonary ductus arteriosus 
(136, 137). Disruption of the EP4 gene results in death of most homozygous EP4 -/- 
neonates within 3 days of birth due to pulmonary congestion and heart failure (136, 137).  
As noted earlier, EP4 mRNA is present in the ductus and works in the dilation of the 
vessel.  EP4 -/- neonates showed full patency of the ductus after birth indicating a critical 
role of EP4 in the ductus.  The EP4 receptor ligands may prove useful in promoting 
closure or maintaining patency of the ductus arteriosus in newborns with congenital heart 
disease.  Additionally, EP4 deficient mice have shown that PGE2-EP4 signalling 
facilitates initiation of skin immune responses by promoting the migration and maturation 
of Langerhans cells.  While PGE2 is produced substantially in skin exposed to antigen, its 
role was unclear. Although Langerhans cells express all four EP subtypes, their migration 
to regional lymph nodes was decreased only in EP4-deficient mice and in wildtype mice 
treated with an EP4 antagonist (138).  Lastly, EP4 deficiency impaired mucosal barrier 
function and induced epithelial loss, crypt damage, and aggregation of neutrophils and 
lymphocytes in the colon. Among the eight prostanoid receptor-deficient mice tested, 
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only EP4-deficient mice and not mice deficient in either DP, EP1, EP2, EP3, FP, IP, or 
TP developed severe colitis with 3% dextran sodium sulfate treatment, which induced 
only marginal colitis in wildtype mice. These studies conclude EP4 maintains intestinal 
homeostasis by keeping mucosal integrity and downregulating immune response (139). 
 
Mice with targeted deletion of the EP3 receptor exhibit an impaired febrile 
response to PGE2, suggesting that EP3 receptor antagonists could be effective antipyretic 
agents (140).  EP3 deficient mice were also used to determine the role of PGE2 in pain 
perception.  EP3 and IP were found to be the major prostaglandin receptors mediating the 
enhanced pain response in mice pre-treated with LPS to induce COX-2 expression (141).  
Additionally, EP3 deficient mice were found to have impaired duodenal bicarbonate 
secretion and mucosal integrity.  The presence of EP3 receptors were found to be 
essential for maintaining duodenal acid secretion and maintaining the mucosal integrity 
against luminal acid (142).  EP3 deficient mice also demonstrated the PGE2 -EP3 
pathway is an important negative modulator of allergic reactions.  Only EP3 deficient 
mice were shown to develop an allergic inflammation that was much more pronounced 
than that in wildtype mice or mice deficient in other EP receptor subtypes. Conversely, an 
EP3-selective agonist suppressed the inflammation (126). A recent study has shown the 
roles of PGE2 signaling in metabolic regulation have expanded beyond the reported 
stimulation of leptin release from adipose tissue to also involve actions mediated by the 
EP3 receptor in the regulation of sleep architecture and feeding behavior (143).  EP3 
deficient mice exhibit increased frequency of feeding during the light cycle of the day 
and develop an obese phenotype under a normal fat diet fed ad libitum.  Although EP3 
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deficient mice showed an increased motor activity, this did not compensate sufficiently to 
offset the increased body weight. These findings further indicate there is a link between 
inflammatory signaling and obesity. 
 
Collectively studies using mice deficient in each EP subtype and subtype-specific 
EP agonists/antagonists have shown interactions between PGE2 and its receptor subtypes 
to be dependent on tissue/cell type and location specific receptor expression, variation in 
PGE2 binding affinities and hence differential receptor activation (144, 145). These 
variables therefore allow PGE2 the ability to mediate highly varied effects on cell biology 
in many different tissue types and in some cases diseases such as cancer. 
 
EP receptors and cancer 
Overexpression of COX-2 and the upregulation of PGE2 production is a common 
finding in many cancers of epithelial origin. Because PGE2 exerts its effects by signalling 
through the EP receptors, the activation of specific EP receptors contributes to the 
importance of PGE2 signalling in the development of several types of cancers. For 
instance, EP1, EP2 and EP4 have been implicated to play a role in breast cancer.  Recent 
reports have demonstrated a possible link between EP4 and the formation of breast 
cancer metastasis (146).  Firstly, all four EP subtypes were found expressed in three 
murine mammary tumor cell lines.  Next it was observed that EP4 antagonists were able 
to reduce tumor metastasis in vivo, however antagonists to EP1, EP2 and EP4 could 
reduce PGE2-induced migration in vitro suggesting selective inhibition of these EP 
subtypes can reduce the metastatic potential of breast cancer cells. EP3 antagonism had 
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no effect on tumor metastasis (146).  Similar to EP4, the lack of EP2 in MMTV-COX-2 
transgenic mice strongly suppressed COX-2–induced effects such as precocious 
development of the mammary gland in virgins and the development of mammary 
hyperplasia in multiparous female mice suggesting disruption of EP2 signalling as a 
chemopreventive approach to breast cancer (147).  EP1 antagonists may also possess 
chemopreventive effects through the induction of apoptosis without any side effects 
(148).  Administration of an EP1 antagonist significantly decreased carcinogen-induced 
breast cancer incidence, multiplicity and volume compared with control animals.  EP1 
expression was present in breast cancer but not in normal tissue.  Breast cancer from mice 
fed the EP1 antagonist showed significantly increased apoptosis suggesting selective 
disruption of PGE2-EP1 signalling as an alternative approach to the use of COX 
inhibitors (148).   
 
Upregulation of COX-2 activity and PGE2 production is also a common event that 
occurs during the formation and progression of skin cancer (149).  The EP2 receptor was 
shown to play a significant role in the protumorigenic action of PGE2 in skin tumor 
development.  Unlike EP3 knockout mice, the EP2 knockout mice produced significantly 
fewer tumors and reduced tumor incidence compared with wildtype mice in a two-stage 
skin carcinogenesis model (150).  Furthermore, UV-irradiated mice lacking EP2 
receptors exhibit decreased proliferation and a poor capacity for epidermal hypertrophy 
in response to UV injury.  Interestingly, in a chronic irradiation model, these animals 
were protected from tumor formation, developing 50% fewer tumors than wildtype 
controls.  Despite this capacity to protect against tumorigenesis, animals lacking EP2 
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receptors grew tumors that were larger in size, with a more aggressive phenotype.  This 
was found to be associated with greater quantities of active matrix metalloproteinases 
than keratinocytes expressing the EP2 receptor, thereby enhancing the invasive potential 
of EP2-/- cells (151).  Drugs designed to block EP1 may also have the potential to be 
used as a chemopreventive agent that reduces the risk of skin cancer development.  
Topical treatment with celecoxib or the specific EP1antagonist ONO-8713 decreased 
inflammation in the skin and significantly reduced the number of tumors after UVB 
exposure and topical treatment (152).  
 
PGE2 significantly enhances cell proliferation and reduces apoptosis in colon 
cancers induced by AOM.  PGE2 increased the incidence and multiplicity of AOM-
induced colon tumors in rats (153).  All four EP receptors were detected in the tumors 
and paired mucosa although EP3 to a lesser extent in the cancers compared to mucosa 
(153).  Genes for each of these receptors have been disrupted and corresponding knock-
out mice produced (129, 136, 140).  EP1, EP2 and EP4 have been implicated to play a 
role in intestinal tumorigenesis using different animal models.  Mice lacking EP4 were 
partially resistant to AOM-induced aberrant crypt foci (ACF,) putative precursors of 
colon cancer, while EP3 deficient mice showed no effect (154, 155).  Either 
pharmacological or genetic inhibition of the EP1 receptor results in a significant 
reduction in colon cancer development, indicating a role for this receptor in colon 
carcinogenesis (155).  Furthermore, one study showed EP2 disruption decreases the size 
and number of intestinal polyps in APCΔ716 mice and that EP2-generated cAMP 
stimulates expression of more COX-2 and vascular endothelial growth factor (VEGF) in 
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the polyp stroma (156). Interestingly, genetic deletion or inhibition of an EP receptor has 
shown consistently a 40-60% decrease in intestinal polyps compared to the 80-90% 
reduction seen with COX deletions using the same animal models.  This suggests more 
than one EP receptor subtype is involved in these models and/or that other prostaglandins 
via their specific receptor may contribute to the promotion of intestinal tumorigenesis.  
 
As PGE2 is implicated to have a very important role in tumorigenesis, with EP 
receptors currently being the only class of prostanoid receptor with a proven link to 
neoplasia, a further chemotherapeutic approach may be to block PGE2 mediated 
signalling events through selective EP receptor antagonism.  This may have advantages 
in allowing some PGE2 signalling while inhibiting specific events more closely 
associated with tumorigenesis.  
 
EP3 receptor variants 
As noted, in addition to the receptor subtypes encoded by different genes, 
alternative splicing can create several variants of the EP3 receptor which differ in their 
carboxy-terminal sequence (Figure 5). The mouse EP3 receptor has three variants, EP3α, 
EP3β, and EPγ (157-159), the bovine EP3 receptor has four variants (158), the rabbit EP3 
receptor has five variants (160, 161), and the human EP3 receptor has eight variants 
(162). Gi activation mediated by the mouse EP3 receptor variants has been well 
investigated.  
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The mouse EP3 receptor splice variants display identical agonist binding 
properties, but are functionally different in their efficiency of G protein activation, the 
specificity of G protein coupling and sensitivity to agonist-induced desensitization.  For 
instance, mouse EP3α and EP3β couple to Gi, but three orders lower concentration of 
agonists were required for EP3α than EP3β for the activation of the Gi protein.  EPα 
undergoes both short and long term agonist-induced desensitization, whereas EP3β 
undergoes neither short nor long term desensitization.  With regards to their agonist-
dependency for Gi activation, the mouse EP3α and EP3γ variants have partially 
constitutive Gi activity, but the EP3β variant has no constitutive Gi activity (163, 164).   
 
A truncated mutant at the splice site of EP3 was generated in order to determine 
the role of the C-terminal tail (164). The mutant receptor retained the ability to couple to 
Gi and showed fully constitutive Gi activity. These results indicate that the C-terminal tail 
of the EP3 receptor is essential for the regulation of agonist-dependent activation of G 
protein. 
 
Despite the vast amount of research performed on EP receptors, little is known on 
the pathological effects of the EP3 splice variants and their signal transduction pathways. 
The EP3 receptor is the one EP receptor that has consistently not been directly involved 
using intestinal tumorigenesis animal models. Examination of mRNA expression levels 
in colon tissue of mice, rats and human by RT-PCR and quantitative RT-PCR shows a 
marked reduction in the EP3 receptor in colon cancer compared to normal mucosa. In 
contrast EP1 and EP2 are found increased in colon cancers (153, 165).  Expression of 
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EP3 mRNA was detected in only one of eleven colon cancer cell lines tested and 
treatment of that one cell line with an EP3 agonist decreased viable cell numbers by 30%.  
Immunohistochemical staining demonstrated rat EP3 protein expressed in normal 
epithelium and some parts of small carcinomas but absent in large carcinomas of the 
colon, suggesting EP3 is downregulated during colon cancer progression.  While 
deficiency in EP3 had no effect on ACF development, an increase in AOM-induced colon 
carcinoma was found in EP3 knockout mice suggesting EP3 may not impact early stages 
as greatly as later stages of colon carcinogenesis. As noted, EP2 and EP4 stimulate 
adenylate cyclase whereas EP3 inhibits cAMP formation, suggesting a possible 
suppressive role against colon carcinogenesis.  In addition to CRC, EP1, EP2 and EP4 
receptors were elevated, whereas EP3 receptor levels were decreased in mammary tumors 
from COX-2/MMTV mice (166).  In contrast to these findings, a recent study reported 
EP3 receptor signaling to play an important role in tumor-associated angiogenesis (167).  
In this context, implanted tumor growth (sarcoma-180, Lewis lung carcinoma) and 
tumor-associated angiogenesis were markedly reduced in EP3 null mice.  Moreover, EP3 
antagonists reduced tumor size in wildtype but had no effect on EP3 null mice.  Using the 
sponge implantation model, it was shown that VEGF expression is significantly reduced 
in EP3 null mice compared to wildtype mice.  The inconsistency between models 
highlights the effects of PGE2 on carcinogenesis ultimately depends on the expression 
pattern of PGE2 receptors which is tissue-specific and model-specific.  Collectively the 
inconsistencies of these studies on EP3 prompted the need for further investigation into 
the role EP3 splice variants and their underlying mechanisms play on tumor cell function. 
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Aims of Dissertation 
The overall aims of this dissertation are: 
1) To characterize the mouse EP3 receptor variants and determine their role on 
tumor cell function. 
Despite the extensive characterization of the EP3 receptor splice variants in cell 
culture systems (157-159, 163, 164), the functional significance of these different C-
terminal splice variants remains uncertain.  The variants are identical over the first 355 
amino acids up to the end of the seventh transmembrane helix, but differ in carboxyl tails.  
The variants may serve different functions and contribute to the diversity of the actions of 
PGE2.  When expressed in a variety of cell lines, the variants display similar affinity for 
PGE2 but differ in coupling to G proteins, agonist-dependent desensitization and in 
agonist-independent constitutive Gi activity.  
 
To investigate the functional differences among the three mouse EP3 (mEP3) 
variants on cell function we expressed the myc-tagged mEP3 α, β, and γ in tumor cells 
and examined downstream signaling pathways activated in these cells utilizing selective 
EP3 agonists.  We focused particularly on calcium mobilization, ERK, Akt and Rho 
activation, as these pathways have been shown activated upon EP3 stimulation.  
Furthermore, as prostanoids can induce receptor internalization we determined whether 
EP3 selective agonists affect the cell surface localization of the mEP3 receptor variants.  
Finally, since activation of the EP3 receptor has been shown to induce stress fiber 
formation and cell migration, we analyzed morphological changes in the tumor cells 
overexpressing the mEP3 receptor variants following agonist stimulation.   
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2) To determine the functional role of the mouse EP3 variants on tumor cell 
growth.   
Several lines of evidence indicate the involvement of EP receptors in tumor 
progression. The rationale behind this aim is that, although EP1, EP2 and EP4 have been 
implicated to play a role in several models of tumorigenesis and types of cancer, EP3 has 
consistently not been shown to promote tumorigenesis (146, 150, 153-155).  We and others 
have shown that EP3 expression is downregulated or absent in various tumor cells (165, 
166, 168).  This suggests the lack of EP3 may confer a growth advantage to tumor cells and 
restoring EP3 expression may have a growth suppressive role. 
 
To examine the effect of the mEP3 variants on tumor cell growth we 
overexpressed each variant in human colon cancer cells (HCT116).  These human colon 
cancer cells lack EP3 (165) as well as COX-2 (169) expression, thus allowing us to 
examine the effects of exogenous EP3 agonists on tumor cell function.  We examined 
populations of mEP3 receptor variant expressing HCT116 for their ability to grow in vitro 
and in vivo.   
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Reagents 
Prostaglandins were purchased from Cayman Chemicals (Ann Arbor, MI). 
MB28767 was a generous gift from Dr. Matthew Breyer (Vanderbilt University), the 
plasmid of constitutively activated RhoA (G14V) was a gift from Dr. Brent Polk 
(Vanderbilt University) and the expression plasmid for Clostridium botulinum C3 toxin 
was a gift from Dr. Richard Neubig (University of Michigan). The expression plasmids 
of constitutively activated and dominant negative G protein subunits αi, α12 and α13 were 
purchased from UMR cDNA Resource Center (University of Missouri, Rolla, MO). 
[3H]PGE2 was purchased from Amersham Biosciences (Piscataway, NJ). Pertussis toxin, 
BAPTA/AM, PD 98059, Y-27632 and wortmannin were purchased from Calbiochem (La 
Jolla, CA). FBS and DMEM were obtained from Hyclone (Logan, UT). 
Penicillin/streptomycin, L-glutamine and G418 was purchased from Invitrogen 
(Carlsbad, CA). Effectene transfection reagent was purchased from Qiagen (Valencia, 
CA) 
 
Expression of mEP3 receptor variants in HEK293 and HCT 116 cells 
The mEP3 variants were subcloned into pcDNA3 (gift from Dr. Ray Harris, 
Vanderbilt University) using EcoRI and XhoI restriction sites and a myc tag (5’-p 
CATGGCAGAACAAAAACTTATTTCTGAAGAAGATCTGCATATGG-3’) was 
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added to each at the extracellular N-terminus using KpnI and NheI sites and where the 
NdeI site is conserved. Cells were maintained at 37ºC in humidified air containing 5% 
CO2 in DMEM supplemented with 10% FBS, 2mM L-glutamine, 100 units ml-1 
penicillin, 100 µg ml-1 streptomycin. HEK293 cells (gift from Dr. Richard Breyer, 
Vanderbilt University) and HCT116 cells (gift from Dr. Ray DuBois, Vanderbilt 
University) were stably transfected with each pcDNA3/mEP3 variant or pcDNA3 using 
Effectene (Qiagen) and cells expressing mEP3 were selected by addition of medium 
containing 600 µg ml-1 G418 at 48 h post-transfection.  Polyclonal populations of each 
mEP3 variant were sorted for equal expression using flow cytometry.   
 
Flow cytometry 
Flow cytometric analysis was performed on vector and mEP3 variant transfected 
and selected cells harvested with 0.25% trypsin; 1 mM EDTA.  Single cells (1 x 106) in 
normal media were incubated with 1 μg of anti-myc (9E10) from Santa Cruz (sc-40, 
Santa Cruz, CA) for 30 minutes at room temperature. Cells were washed three times with 
sterile PBS and incubated with phycoerythrin-conjugated anti-mouse secondary antibody 
(Jackson Immunoresearch, West Grove, PA) for 30 minutes at room temperature. Cells 
were washed three times, resuspended in sterile PBS, and analyzed using a FACSAria 
instrument (BD Biosciences, San Jose, CA).  Cells were sorted for equal expression to 
avoid potential pitfalls related to monoclonal populations.  
 
Preparation of cell membranes 
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Membranes for binding experiments were harvested once cells were sorted and 
analyzed for equal expression of each mEP3 variant. Cells were rinsed once with ice-cold 
PBS containing 1 mM EDTA and lysed by scraping in lysis buffer (15 mM HEPES, pH 7.6, 
5 mM EDTA, 5 mM EGTA, and 2 mM phenylmethylsulfonyl fluoride) and passage through 
a 21-gauge needle five times. To collect membranes, the cell lysate was layered on a 60% 
sucrose cushion and centrifuged at 150,000g for 1 hour at 4°C. The membrane fraction was 
passed through a 26-gauge needle five times and frozen at –80°C. Protein concentrations 
were determined by the BCA assay (Pierce). 
 
Radioligand binding assays 
 For one-point binding experiments, 50 μg membrance protein in the presence of 2 
nM of [3H] PGE2 in the presence or absence of 5 μM sulprostone was incubated at 30°C 
for 2 h in binding buffer [25 mM HEPES (pH7.4), 1 mM EDTA, 5 mM MgCl2, 140 mM 
NaCl, 5 mM KCl]. The binding reaction was terminated by the addition of 3 ml of ice-
cold binding buffer and rapidly filtered under vacuum over Whatman GF/F filters 
(Clifton, NJ). Filters were washed three times with 3 ml of ice-cold binding buffer, dried, 
and counted in 4 ml of CytoScint ESTM liquid scintillation fluid (MP Biomedicals LLC, 
Solon, OH).  For saturation binding experiments 5 μg of membrane protein was 
incubated in binding buffer for 2 hours at 30°C with various concentrations of [3H] PGE2. 
Nonspecific binding was determined in the presence of 5 μM unlabeled PGE2 and 
reaction carried out as above. Three independent experiments were performed in 
triplicates. 
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Intracellular calcium mobilization assay 
HEK293 cells overexpressing mEP3 variants were plated in 96-well plates 
(50,000 cells/well). Mobilization of intracellular calcium was measured on a FLEXstation 
system (Molecular Devices, Sunnyvale, CA) using the FLEXstation calcium assay kit 
according to the manufacturers instructions. Briefly, cells were labeled with calcium 
assay reagent resuspended in Hanks’ balanced salt solution/20 mM HEPES, pH 7.4, for 1 
hour at 37°C before measurement. MB28767 was added to parallel wells in a volume 
equivalent to 10% of the final well volume while fluorescence was monitored, λex= 485 
nm, λem = 525 nm. In each case, the experiment was terminated by addition of 10 μM 
ionomycin to determine maximum Ca2+ response. Three independent experiments were 
performed in triplicates. 
 
Morphology and immunofluorescence analysis 
To visualize actin, ZO-1 and mycEP3 variant receptors, cells in normal media 
were plated at a density of 2 x 105 cells into 8-chamber slides (Falcon; Becton Dickinson, 
Heidelberg, Germany) and cultured 48 hours. Cells were treated for 4 hours with 0.1 μM  
PGE2, sulprostone, MB 28767, butaprost or vehicle control then gently washed in PBS, 
fixed in 4% formaldehyde in PBS for 20 minutes, permeabilized with 0.1% Triton X-100 
in PBS for 3 minutes and blocked in PBS/3% BSA for 1 hour at room temperature 
followed by the addition of rabbit anti-ZO-1 (Zymed Laboratories; 1:100 dilution in 
PBS/3% BSA) or mouse anti-myc (Santa Cruz; 1:100 dilution in PBS/3% BSA) 
overnight at 4°C. After two washes in PBS, cells were incubated with rhodamine-
phalloidin (Molecular Probes, Eugene, OR; 1:1000 dilution in PBS/3% BSA) and 
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fluorescein-conjugated anti-rabbit or anti-mouse secondary antibody (Jackson; 1:200 
dilution in PBS/3% BSA) in the dark for 1 hour at room temperature.  Chamber slides 
were washed twice in PBS, fixed and mounted using Vectashield mounting medium for 
fluorescence (Vector Laboratories, Burlingame, CA) and visualized using an 
epifluorescence microscope (Nikon).  
 
 Cell morphology was evaluated whereby 2 x 105 cells were plated in normal 
medium into 24 well plates (Falcon).  For replacement experiment, the cell media was 
treated with 0.1 μΜ butaprost, MB 28767 or vehicle for 4 hours then replaced with 
normal media and cells photographed at indicated time points.  For the inhibitors study 
cells were either transfected (Effectene) 48 hours prior to ligand treatment or treated with 
inhibitors  (PD98059 5 μM, Wortmannin 100 nM, IBMX 0.5 mM, Bapta 5 μM, Y-27632 
5 μM) overnight prior to treatment with 0.1 μΜ MB 28767 or vehicle for 4 hours.  Cells 
were gently washed in PBS, fixed in 4% formaldehyde in PBS for 20 minutes and 
visualized using an inverted microscope (Nikon).  Three independent experiments were 
performed. 
 
Rho GTP pulldown assay 
1 x 106 serum-starved cells treated with 0.1 μΜ MB28767 or vehicle for 15 
minutes were washed with ice-cold PBS and lysates were prepared using Rho activation 
assay kit (Upstate Biotechnology, Lake Placid, NY).  GTP-bound Rho was precipitated 
with RBD agarose beads and measured in pellets by Western blot with anti-Rho antibody, 
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using crude cell extracts for normalization.  Densitometry was performed using Labworks 
Image software (Upland, CA). Three independent experiments were performed. 
 
 
Western blot analysis 
 To evaluate the effects of mEP3 activation on ERK, p38, and Akt 
phosphorylation, semi-confluent HEK cells were serum-starved for 24 hours and then 
treated with 0.1 μΜ MB 28767 or vehicle for 15 minutes. The cells were washed with 
PBS and lysed in cell lysis buffer (#9803; Cell Signaling Technology, Beverly, MA) and 
centrifuged for 10 minutes at 14,000 rpm. Cell lysates were resolved by SDS/PAGE 
(10% gels; 30 μg of total protein/lane) and transferred to Immobilon-P membranes. 
Membranes were incubated with a rabbit antiphospho-ERK, anti-phospho-p38, or 
antiphospho-Akt antibody (all from Cell Signaling Technology) overnight at 4°C 
followed by the anti-rabbit HRP-conjugated secondary antibody.  Immunoreactive 
proteins were visualized using Western Ligntning Chemiluminescence reagent plus 
(PerkinElmer, Boston, MA) according to manufacturers’ instructions. Equal loading was 
verified by stripping the membranes in 50 mM Tris-HCl, pH 6.5, containing 2% SDS and 
0.4% β-mercaptoethanol for 1 h at 55 °C, and re-probing with a rabbit anti-p38 (Cell 
Signaling Technology). Three independent experiments were performed. 
 
To confirm expression of selective G protein alpha subunits, total lysates of cells 
transfected 48 h prior using Effectene according to manufacturer’s instructions were 
collected, resolved and transferred as described above. Membranes were incubated with 
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rabbit anti-Gαi-2 (T-19), anti-Gα12 (S-20) or anti-Gα13 (A-20; all from Santa Cruz) 
overnight at 4°C followed by the anti-rabbit HRP-conjugated secondary antibody. Equal 
loading was verified by probing with rabbit anti-FAK (C-20; Santa Cruz). Three 
independent experiments were performed. 
 
Cell Proliferation 
Cell proliferation was evaluated by seeding a 96-well plate with 5 x 103 cells/well in 
DMEM containing 2.5% FCS and left to incubate overnight at 37°C in 5% CO2. Cells were 
pulsed for 48 h with [3H] thymidine (1 µCi/well) with or without 0.1 µM of PGE2, MB-
28767, sulprostone or butaprost. For Rho inhibitor study, 10 µM of Y-27632 was added to 
appropriate wells.  The cells were then washed three times with PBS, lysed in 2% SDS (100-
µl final volume), and the lysates measured with a beta counter.  Four independent 
experiments were performed in quadruplicates. 
 
Tumor Growth in nude mice 
Athymic nude mice were challenged by a single subcutaneous injection with 0.2 ml 
of 1 x 106 trypsinized cells washed three times in PBS. The growth of tumors was evaluated 
twice weekly and all mice were sacrificed at 35 days. All mice were anesthetized and 
euthanized by Institutional Animal Care and Use Committee approved procedures. All tumor 
tissue was harvested, measured, weighed, embedded in ornithine carbamyl transferase and 
frozen on dry ice to prepare frozen sections. 15 mice were used in our HEK293 cell studies 
and 14 mice were used in our HCT116 cell studies. Volume was determined according to the 
equation V = [L x W2] x 0.5, where V = volume, L = length, and W = width. 
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Statistical analysis 
 The student’s t test was used for comparisons between two groups, and analysis of 
variance using Sigma-Stat software for statistical difference between multiple groups.  
p<0.05 was considered statistically significant.   
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CHAPTER III 
 
CHARACTERIZATION OF THE MURINE EP3 RECEPTOR VARIANTS 
 
Introduction 
 
Prostaglandin E2 exhibits a broad range of biological actions in diverse tissues 
through its binding to specific transmembrane receptors.  PGE2 receptors are subdivided 
into four distinct G protein-coupled receptor (GPCR) subtypes designated EP1, EP2, EP3 
and EP4. The EP1 receptor couples to phospholipase C, the EP2 and EP4 receptors 
couple to the stimulation of adenylyl cyclase and the EP3 receptor couples to inhibition 
of adenylyl cyclase. In mouse, alternative splicing generates three EP3 variants, α, β, and 
γ, containing carboxyl tails of 30, 26 and 29 amino acids that do not share any structural 
motifs or hydrophobic features. The variants are identical over the first 355 amino acids 
up to the end of the seventh transmembrane helix, but differ in carboxyl tails.  The 
variants may serve different functions and contribute to the diversity of the actions of 
PGE2 (Figure 3 and Table 1). 
 
Although all EP3 splice variants bind PGE2 and the EP3 selective agonists 
MB28767 and sulprostone with similar affinity, they are functionally different in their 
efficiency of G-protein activation, the specificity of G-protein coupling and sensitivity to 
agonist-induced desensitization. Gi activation mediated by the mouse EP3 receptor 
variants has been well investigated.  For instance, the mouse EP3α and EP3γ variants 
have constitutive Gi activity, but the EP3β variant has no detectable constitutive Gi 
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activity (163, 164).  While EP3α and EP3β signaling have been shown to inhibit the 
activation of adenylate cyclase, EP3γ signaling has been shown to have both stimulatory 
and inhibitory effects of adenylate cyclase(159).  Despite extensive studies to elucidate 
the significance of these spliced tail variants, it is yet unclear their distinct roles on cell 
function. 
 
Although initially described as coupled to inhibiting cAMP production via Gi, 
splice variants have been described to couple to different signalling pathways.  Activation 
of the mouse EP3α, EP3β and EP3γ receptors are known to lead to intracellular calcium 
mobilization in a pertussis toxin (PT)-sensitive manner.  This calcium mobilization 
mediated by the EP3 receptor is conducted by the Gβγ subunits from the Gi protein, since 
the PLCβ isoform is activated by these subunits (170).  In addition to calcium, the EP3 
variants signal through the small GTP-binding protein Rho to induce neurite retraction in 
PC-12 cells (118, 119) as well as induce stress fiber formation in MDCK cells (120). 
 
Despite extensive studies, the functional significance of these alternatively spliced 
variants remains unclear. A truncation mutant at the splice site of EP3 was generated in 
order to determine the role of the C-terminal tail (164).  The mutant receptor retained the 
ability to couple to Gi and showed fully constitutive Gi activity.  These results indicate 
that the C-terminal tail of the EP3 receptor is essential for the regulation of agonist-
dependent activation of G protein.  To investigate the functional difference between the 
three mouse EP3 variants on cell morphology and function we generated populations of 
HEK293 cells expressing the myc-tagged mouse EP3α, EP3β and EP3γ receptor variants 
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and examined these populations for activation of signal transduction pathways and 
morphology.  We used HEK293 cells as they are commonly used to study prostanoid 
receptors, they maintain robust expression of the mEP3 variants over many passages and, 
importantly for our second aim, HEK293 cells are tumorigenic in nude mice. 
 
Results 
 
The mEP3 receptor variants are expressed at similar levels 
 
To characterize the three mEP3 variants on cell morphology and function, 
HEK293 cells were stably transfected with pcDNA3 mEP3 α, β, and γ myc-tagged at the 
extracellular N-termini. The specificity of the myc antibody (9E10) was demonstrated by 
comparing flow cytometric analyses of mEP3 receptor variant transfected HEK293 cells 
with cells transfected with only the vector pcDNA3 (Figure 5A). Cell populations 
expressing comparable levels of the receptor variants were isolated by FACS using the 
9E10 anti-myc antibody. 
 
To demonstrate functionality of the mEP3 receptor variants we next confirmed 
native ligand binding by isolating membrane preparations and incubating equal amounts 
of membrane protein with radioactive PGE2 in the absence or presence of saturating 
levels of the selective EP3 agonist, sulprostone (Figure 5B). PGE2 binding to the EP3 
variants was similar and equally inhibited by cold sulprostone.  In contrast, vector-
transfected cells exhibited no specific PGE2 binding activity.  Finally to confirm 
comparable receptor number a saturation isotherm binding assay was performed and 
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revealed high-affinity specific binding of radioactive PGE2 of membrane protein and no 
specific binding on membrane proteins from vector transfected cells (Figure 5C). 
 
Signaling by the mEP3 receptor variants mobilizes intracellular calcium as well as 
activates ERK and Rho 
 
To characterize the intracellular signaling pathways activated by the mEP3 
receptor variants we first examined the PI3K and MAPK pathways in stably transfected 
HEK293 cells, as PGE2 has been shown to activate both of these pathways (Figure 6A) 
(171-173).  Treatment with MB28767 had no effect on the PI3K pathway as seen by 
phosphorylation of Akt or the p38 MAPK pathway as seen by phosphorylation of p38. In 
contrast, we consistently observed activation of ERK in all three mEP3 receptor variant 
transfected cells within 15 minutes of stimulation with MB28767, but not in vector 
transfected cells.  
 
As activation of the mEP3 receptor variants leads to increased intracellular 
calcium (170), the ability of the two selective EP3 agonists MB28767 and sulprostone 
(not shown) to induce intracellular calcium mobilization was determined. Each of the 
three mEP3 variants mobilized calcium in a concentration and time dependent manner 
after stimulation with EP3 agonists (Figure 6B & 6C). In contrast, no calcium 
mobilization was detected in vector-transfected cells.  Thus, each of the three mEP3 
receptor variants was functionally expressed in HEK293 cells.  Lastly, since EP3 receptor 
variants have been shown to induce neurite retraction in PC-12 cells and mediate stress 
fibers in MDCK cells via Rho (119, 120, 174), we evaluated the effect of mEP3 receptor 
variant activation on Rho GTPases.  
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Figure 5. The mEP3 receptor variants are expressed at similar levels. (A) Flow cytometric analysis of 
stably transfected HEK293 cells with mEP3 receptor variants using fluorescent anti-myc antibody. mEP3 
receptor variant expression is displayed by a shift in mean fluorescent intensity compared to vector 
transfected HEK293 cells. (B) One-point ligand binding assay on membranes from HEK cells stably 
expressing mEP3 receptor variants incubated at 30°C for 2 h with 2 nM [3H]PGE2 in the absence or 
presence of 5 μM sulprostone to confirm equal expression on cell membrane; Membrane preparations 
assayed in triplicates. *p < 0.05 versus vector control. #p < 0.05 versus [3H]PGE2 only control. (C) 
Saturation isotherm analysis of [3H]PGE2 binding to mEP3 receptor variants expressed in HEK293 cells. 
Membranes isolated from HEK293 cells stably expressing mEP3 receptor variants were incubated with 
varying concentrations of [3H]PGE2 in the absence (total binding) or presence (nonspecific binding) of 10 
μM PGE2, as described under Materials and Methods. Specific binding was determined to be the difference 
between total and nonspecific binding and is shown above. Values in the insert box represent the mean +/- 
SD of one representative experiment performed in triplicate.These data are representative of three 
independent experiments. 
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Figure 6. Signaling by the mEP3 recpetor variants mobilizes intracellular calcium as well as activates 
ERK and Rho.  (A)  To investigate the signal transduction pathways activated by the mEP3 receptor 
variants, lysates were collected following overnight serum-starvation and treatment with 0.1 μM MB-28767 
for 15 minutes. As described under Materials and Methods, western blot analysis was performed using 
anti-phospho-Akt, anti-phospho-ERK, anti-phospho-p38, and anti-p38 MAPK specific antibodies. The 
concentration dependence (B) and time course (C) of MB-28767 (shown) and sulprostone-induced 
intracellular calcium mobilization for the three mEP3 receptor variants and vector control with stimulation 
by 0.1 µM selective agonists.  (D)  Rho pulldown assay performed on HEK293 cells stably expressing 
mEP3 receptor variants or vector alone following overnight serum-starvation and treatment with 0.1 μM 
MB-28767 or vehicle for 15 minutes. Total Rho levels were determined from whole cell lysates as shown 
in the bottom panel. Cell lysates were separated by a 15% SDS-polyacrylamide gel followed by 
immunoblotting with anti-Rho antibody, as described under Materials and Methods. Samples for pull-down 
assay and total Rho were from the same homogenates. The results shown are representative of three 
independent experiments that yielded similar results. 
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We used the Rho-binding domain of RhoA effector, rhotekin, to affinity precipitate active 
RhoA, as a direct readout for RhoA activation (Figure 6D).  We also used Rac1- and 
Cdc42-binding domain of Rac1 and Cdc42 effector, PAK to affinity precipitate active 
Rac1 and Cdc42 as a direct readout for Rac1 and Cdc42 activation (not shown). HEK293 
cells stably transfected with mEP3 receptor variants or vector were stimulated with 
MB28767 for 15 minutes. Densitometry readings of treated versus untreated variants 
demonstrated a 3- to 4-fold increase in RhoA activity. However, all mEP3 receptor 
variants failed to activate Rac1 or Cdc42 suggesting a mechanism to regulate the 
specificity toward different Rho GTPases.  
 
 
Differential surface localization by the mEP3 receptor variants 
 
The molecular regulation of EP3 splice variant trafficking is yet unclear. 
Typically C-tail splice variants show differences in internalization and trafficking. For 
example the human EP3 receptor comprises eight variants that differ solely in their 
carboxyl-tail. Upon PGE2 stimulation EP3.I internalizes, EP3.II, EP3.V, EP3.VI and 
EP3.f internalize to a lesser extent and EP3.III and EP3.IV do not internalize at all 
indicating the importance of the C-tails in determining their degree of PGE2-induced 
internalization (162).  Here we analyze the role of the three mouse C-terminal tails on 
localization of the mEP3 variants in HEK293 cells before and after treatment with 
selective EP3 agonists by immunofluorescence and FACS analysis. 
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Figure 7. Differential surface localization by the mEP3 receptor variants. (A) To confirm mEP3 
receptor variant expression, cells were stained with an anti-myc antibody following 0.1 µM MB28767 
treatment or vehicle for 4 h. The results shown are representative of three independent experiments that 
yielded similar results. The bar represents 10 μm. (B) & (C) Mean intensity fluorescence of HEK293 cells 
(B), HCT116 cells and SW480 cells (C) treated with MB28767 over vehicle for four hours.  The results 
represent the average of three independent experiments. *p < 0.05. 
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In order to confirm EP3 expression and localization in HEK293 cells before and 
after treatment with selective EP3 agonists we performed immunofluorescence staining 
on HEK293 cells expressing each of the three mouse variants or vector alone.  We 
observed for changes in EP3 expression on the cell surface before and after treatment 
with MB28767 by staining with an anti-myc antibody (Figure 7A). The specificity of the 
anti-myc antibody in immunofluorescence studies was apparent from the observation that 
vector transfected cells showed no fluorescence regardless of treatment while the variants 
showed intracellular and cell-surface localization. Stimulation with MB28767 increased 
the level of EP3 variant at the cell surface within four hours of EP3 activation. As this 
result was not quantitative, we next examined this interesting qualitative observation 
further using flow cytometry analyses to determine the mean intensity flurescence of EP3 
receptors before and after stimulation with selective agonist. 
 
We next examined EP3 surface localization by flow cytometry using the anti-myc 
antibody before and after stimulation with MB28767 for four hours in HEK293 cells 
(Figure 7B).  Cell surface localization of the EP3α receptor variant decreased after a four 
hour incubation period with MB28767 stimulation while the levels of membrane-
associated EP3β and EP3γ receptors increased by 2- to 3-fold over unstimulated. 
Interestingly, two colon cancer cell lines we stably transfected with the mEP3 receptor 
variants, namely HCT116 and SW480 cells, show an increase in plasma membrane 
localization of the three variants after stimulation with MB28767 for four hours 
compared to untreated (Figure 7C).  HCT116 EP3β and HCT116 EP3γ show relatively 
high expression at baseline compared to HCT116 EP3α over cell passages.  Treatment 
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does not significantly increase EP3 surface localization for EP3β or EP3γ however 
treatment did significantly increase EP3α plasma membrane localization two fold. This 
may be due to the fact that EP3α downregulates its cell surface expression unlike EP3β 
and EP3γ and upon stimulation enhances its downstream cell function with increased cell 
surface expression.  Similarly, SW480 EP3γ cells significantly downregulate their cell-
surface expression over several passages. However, MB28767 stimulation led to a 
dramatic 5- to 6-fold increase of EP3γ receptor to the cell surface (Figure 7C).  In this 
study, we examined agonist-induced internalization of the mouse EP3 variants. In 
conclusion, our results indicate that the C-tail of the mouse EP3 variants is important in 
determining their degree of internalization mediated by receptor agonists. 
 
Activation of the mEP3 receptor variants induces a morphological change characterized 
by enhanced cell-cell contact 
 
It has been reported that the formation of stress fibers by the mEP3 receptor 
variants in MDCK cells involve Rho (120).  Since we have found Rho activated by EP3 
signaling and RhoA mediates the assembly of stress fibers and the actin cytoskeleton, we 
next examined the morphology of HEK293 cells stably expressing the mEP3 receptor 
variants or vector by immunofluorescence microscopy in the absence or presence 
MB28767. Rhodamine-conjugated phalloidin was used to visualize the actin cytoskeletal 
changes induced by MB28767 (Figure 8A).  All three mEP3 receptor variants stimulated 
with MB28767 caused HEK293 cells to form clusters within four hours of activation 
while vector and untreated variant cells were well dispersed with fibroblast-like foot 
processes evident. The time course of EP3-induced clustering was similar for the three  
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Figure 8. Activation of the mEP3 receptor variants induces a morphological change that enhances 
cell-cell contact. (A) Vector-transfected and mEP3-expressing HEK293 cells were treated with vehicle or 
0.1 μM MB28767.  After four hours, the cells were stained with rhodamine-phalloidin and (B) anti-ZO-1 
antibody to visualize the cytoskeleton and tight junctions, respectively.  Scale bar, 20 μm.   
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variants. We next examined whether this morphological change enhanced cell-cell 
contact by localization of ZO-1, a marker for tight junctions. While vector and untreated 
variant cells displayed punctate staining for ZO-1, the three variants stimulated with 
MB28767 led to enhanced membrane-associated ZO-1 within four hours of EP3 
activation (Figure 8B).  As this experiment takes place over a four hour period and 
immunoblots for ZO-1 showed no increase in ZO-1 protein levels (not shown), we 
conclude that the enhanced cell-cell contact in response to EP3 activation is due to an 
increase in membrane localization and not to an increase expression level of cell adhesion 
molecules.  These results indicate activation of the mEP3 receptor variants equally cause 
a morphological change which is characterized by enhanced cell-cell contact. 
 
The morphological change induced by the mEP3 receptor variants is both physiologically 
relevant and specific to EP3 activation 
 
To confirm the EP3-induced morphological change is physiologically relevant we 
next stimulated HEK293 cells expressing mEP3 variants or vector alone with native 
ligand, PGE2 (Figure 9A). In addition, to confirm the morphological change is specific to 
EP3 activation we stimulated vector and mEP3 expressing HEK293 cells with the EP1/3 
selective agonist, sulprostone, or the structurally similar EP2 selective agonist, butaprost 
(Figure 9A). Although we only show mEP3γ cells, all three variants expressed in 
HEK293 cells were observed to cluster and enhance cell-cell contact when stimulated 
with PGE2 or sulprostone within four hours of EP3 activation similar to MB28767. No 
changes were observed in vector transfected cells. Butaprost had no effect on 
morphology after 4, 24 or 48 hours of EP2 activation confirming the enhanced cell-cell 
contact as an EP3 specific effect.  
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Figure 9. The morphological change induced by the mEP3 receptor variants is both physiologically 
relevant and specific to EP3 activation. (A)  Vector and mEP3 HEK293 cells (mEP3γ shown only) were 
treated with vehicle or 0.1 μM PGE2, sulprostone, or butaprost.  After four hours the cells were stained with 
rhodamine-phalloidin and anti-ZO1 antibody to visualize actin and tight junctions, respectively.  Scale bar, 
20 μm. (B) The cells indicated were treated with 0.1 μM MB28767, butaprost or vehicle. After 4 hours the 
media was replaced with media lacking prostanoid and cells were photographed 4, 24 and 48 hours after 
medium replacement. The images shown are representative of three independent experiments.  Scale bar, 
100 μm 
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We examined whether this morphological change can be reversed by replacing 
the media of cells stimulated with MB28767 for four hours with normal media for 4, 24 
and 48 hours (Figure 9B) and 72 hours (not shown).  We found the EP3-induced  
morphological change could not be reversed by the removal of agonist and replacement 
with normal media. This suggests EP3 activation has a lasting effect on cell morphology 
even after ligand is degraded and unavailable to activate its receptor. 
 
The morphological change induced by mEP3 is mediated by RhoA 
To explore the mechanism by which mEP3 variants induce a morphological 
change in HEK293 cells, we assessed signaling pathways shown activated by EP3 
receptor variants. We used selective pharmacological inhibitors to block EP3-induced 
morphological changes. We have only shown EP3γ but this experiment was performed 
with all three variants and empty vector transfected HEK293 cells multiple times (Figure 
10A). We used forskolin and IBMX to elevate cAMP levels, H-89 to inhibit PKA, BIM 
to inhibit PKC, or BAPTA/AM, a calcium chelator, but none of these were able to block 
the morphological changes induced by EP3 activation. Similarly, although we have 
shown EP3 activation to stimulate ERK activation, the MEK inhibitor, PD98059, or a 
PI3K inhibitor, wortmannin were unable to block the morphological change. In contrast, 
Y-27632, a rho kinase inhibitor or expression of the C3 Clostridium botulinum toxin, 
which inactivates Rho, blocked the mEP3-induced morphological change in all three 
variants. Expression of the C3 toxin was confirmed by comparing RhoA activation after 
MB28767 treatment in mEP3 expressing HEK293 cells with and without C3-transfection 
(Figure 10B). Active Rho and a morphological change were evident exclusively in mEP3  
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Figure 10. The morphological change induced by mEP3 is mediated by RhoA. (A) mEP3-expressing 
HEK293 cells (mEP3γ shown only) were serum-starved for 12 hours in the presence or absence of PD-
98059 (5 µM), wortmannin (100 nM), IBMX (0.5 mM), 5 µM BaptaAM (5 µM), Y-27632 (5 µM) or 
transfected for 48 h with the C3 toxin expression plasmid.  Cells were subsequently treated with vehicle or 
0.1 μM MB28767 and their morphology evaluated 4 hours after treatment.  (B) Rho pulldown assay was 
performed on cells lysates of serum-starved vector- and mEP3-expressing HEK293 (mEP3γ shown only) 
cells untransfected or transfected 48 h prior with C3 toxin and treated for 15m with MB28767.  GTP-Rho 
was detected by immunoblotting with anti-Rho antibody (top).  Total cell lysates were used to detect the 
levels of total Rho (bottom). (C) The cells indicated were transfected with vector control or dominant 
active Rho (DARho) and the levels of Rho were evaluated 48 hours after transfection by Western blot 
analysis in 30 μg of total cell lysates.  (D)Membranes were subsequently incubated with anti-ERK antibody 
to verify equal loading. 
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variant expressing HEK293 cells after MB28767 treatment yet not in the presence of the 
C3 toxin.  This indicates that the mEP3 receptor variant-induced morphological change is 
mediated by Rho. 
To further examine the Rho pathway as a putative mechanism we used a 
dominant active construct of Rho (G14V) to determine whether this was sufficient to 
induce the morphological change in vector transfected cells and in all three variants in the 
absence of ligand.  Although only EP3γ is shown, all three variants responded similarly 
in that overexpression of dominant active Rho was able to induce the morphological 
change in both vector and mEP3 variant expressing HEK293 cells in the absence of 
selective EP3 agonists (Figure 10C). To confirm overexpression of dominant active Rho 
construct in transfected cells, an immunoblot for total Rho is shown (Figure 10D). These 
results further suggest the EP3-induced morphological change characterized by enhanced 
cell-cell contact is mediated by Rho. 
 
G12 and G13 may regulate the mEP3 receptor variant-induced morphological change. 
 
Among classical second messenger pathways, the EP3 receptor variants are 
coupled to adenylate cyclase inhibition through Gi. However pertussis toxin (PT) 
treatment did not suppress the morphological change induced by EP3 agonists (data not 
shown) indicating that this action is not mediated by Gi. Pretreatment with forskolin or 
IBMX, both of which drive cAMP levels up in cells, failed to block the EP3-induced 
morphological change suggesting this action is not mediated by Gs either.  These 
observations suggest that the EP3 receptor variants are not coupled to adenylate cyclase 
but to a PT-insensitive heterotrimeric G-protein other than Gs or Gq.   
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Figure 11. G12 and G13 may regulate the mEP3 receptor variant-induced morphological change.  (A) 
The cells indicated were transfected with vector or dominant active Gi, G12 or G13.  Forty-eight hours later 
cell morphology was evaluated in 4 hours vehicle-treated or MB28767-treated (not shown) cells.  (B) The 
cells indicated were transfected with the constructs indicated above and the levels of these G protein alpha 
subunits were evaluated 48 hours after transfection by western blot analysis in 30 μg of total cell lysates.  
Membranes were subsequently incubated with anti-FAK antibody to verify equal loading.  
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We have shown thus far that EP3 induces a morphological change dependent on 
Rho activation.  Several reports have shown that constitutively activated G12 and G13 can  
stimulate Rho-dependent stress fiber formation and focal adhesion assembly (119, 120, 
174).  As G12 and G13 are PT-insensitive G proteins, we postulated that the EP3 receptor 
variants may regulate morphology through G12 and/or G13. To test this hypothesis we 
transfected constitutively activated Gi as a negative control, G12 and G13 in HEK293 cells 
stably transfected with either vector or mEP3 variants. We found that both constitutively 
activated G12 and G13 can induce a morphological change in the absence of ligand in both 
vector and mEP3 receptor variant transfected HEK293 cells similar to MB28767 treated 
and dominant active Rho transfected HEK293 cells (Figure 11A). To confirm 
overexpression of constitutively activated Gi, G12 and G13 constructs, cell lysates were 
analyzed by western blot for Gi, G12 and G13 with the appropriate anti-G-protein antibody 
(Figure 11B). We found robust overexpression consistently in each of our experiments.  
This suggests that G12 and G13 may transduce the EP3-mediated Rho activation causing a 
morphological change which enhances cell-cell contact. 
 
The mEP3 receptor variant-induced morphological change is likely mediated by G12 
 
To determine whether G12 and/or G13 transduces the EP3-mediated Rho 
activation, dominant negative constructs of Gi, G12 and G13 were overexpressed in vector 
or mEP3 expressing HEK293 cells (mEP3γ shown). Cells were treated with MB28767 
(100nM) and their morphology evaluated 4 hours after agonist treatment (Figure 12A). 
Whereas dominant negative Gi and G13 had no effect on blocking the EP3-induced 
morphological change, expression of the dominant negative G12 prevented cells from  
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Figure 12. The mEP3 receptor variant-induced morphological change is likely mediated by G12.  (A) 
mEP3-expressing HEK293 cells (mEP3γ shown only) were transfected with vector control or dominant 
negative Gi, G12 or G13.  Forty-eight hours later the cells were either treated with vehicle or 0.1 μM 
MB28767 and their morphology was evaluated 4 hours after treatment. Images are representative of three 
independent experiments.  (B) mEP3-expressing HEK293 (mEP3γ shown only) were transfected with the 
constructs indicated above and the levels of these G protein alpha subunits were evaluated 48 hours after 
transfection by western blot analysis in 30 μg of total cell lysates.  Membranes were subsequently 
incubated with anti-FAK antibody to verify equal loading. 
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clustering and developing a more epithelial-like morphology.  To confirm overexpression 
of the dominant negative constructs, cell lysates were analyzed by Western blot analysis 
with the appropriate G protein specific antibody (Figure 12B).  These results strongly 
suggest the mEP3 receptor variants induce a morphological change via a G12-Rho 
pathway in HEK293 cells. 
 
  
Conclusions 
 
The most distinctive feature of the EP3 receptors is the diversity generated by 
multiple alternative splice variants that generate alternate C-terminal tails of this receptor 
subtype.  Here we aimed to characterize the mouse EP3 receptor variants and determine 
their functional differences in HEK293 cells.  These cells consistently overexpress 
robustly our receptor variants and they are widely used to study prostanoid receptors.  
Cell populations overexpressing each variant were isolated by flow cytometry for equal 
expression before characterizing variants for their functional significance.  Once we 
confirmed cell populations for equal expression, native ligand binding and equal receptor 
number, we analyzed variants for their signal transduction usage.  The mEP3 receptor 
variants each mobilized calcium similarly in both a time and dose-dependent manner.  
Interestingly they all activated the ERK, but had no effect on the PI3K or p38 MAPK 
pathways after treatment with a selective agonist for EP3.  We also observed Rho 
activation within 15 minutes of EP3 activation in all three variants however they each 
failed to activate Rac1 or Cdc42 suggesting a mechanism to regulate the specificity 
toward different Rho GTPases. 
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When examining HEK293 cells for mEP3 receptor expression by 
immunofluorescence, interestingly we found an intense staining on the cell surface for 
mEP3 after activating variants with a selective EP3 agonist for 4 hours.  Quantitatively 
by flow cytometry we found cell surface localization of the EP3α receptor variant 
decreased while EP3β and EP3γ increased by 2- to 3-fold over unstimulated. Two colon 
cancer cell lines stably expressing mEP3 variants also showed an increase in plasma 
membrane localization after stimulation. One colon cancer cell line in particular 
consistently demonstrated a dramatic 5- to 6-fold increase of EP3γ receptor with 
stimulation. Our results indicate that the C-tail of the isoforms is important in 
determining their degree of PGE2-induced internalization 
 
Lastly we observed EP3 variants to induce a morphological change characterized 
by enhanced cell-cell contact.  We determined this morphological change to be both 
physiologically significant, EP3 specific and irreversible, hence a long-lasting effect of 
EP3 activation.  We found the mechanism of this morphological change to be likely G12 
mediated and requiring Rho activation. 
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CHAPTER IV 
FUNCTIONAL ANALYSIS OF THE MURINE EP3 RECEPTOR VARIANTS ON 
TUMOR CELL GROWTH 
 
Introduction 
Pharmacological and genetic inhibition studies have shown EP1, EP2 and EP4 to 
play a role in tumorigenesis using several mouse models for different types of cancer 
(146-148, 150-152, 154, 155).  In contrast, the EP3 receptor is the only receptor subtype 
not directly implicated in tumorigenesis (154-156).  For instance, EP3 receptor 
expression was decreased in colon cancer from mice, rats and humans when compared to 
normal mucosa (165). Similar to colon cancer, EP3 receptor levels were found decreased 
in mammary tumors suggesting the silencing of EP3 during tumor development is not 
specific to cancers in the colon (166). Interestingly, deletion of the EP3 receptor does not 
alter early stages of colon cancer progression, namely aberrant crypt foci development, 
whereas EP1, EP2, and EP4 receptors were implicated in small intestinal polyp formation 
(154-156).  However, in contrast to the other EP receptors, an increase in carcinogen-
induced colon carcinoma was found in EP3-null mice, suggesting EP3 may impact later 
stages of colon carcinogenesis (165). Furthermore, only one of eleven human colon 
cancer cell lines was shown to express EP3 and when that cell line was treated with an 
EP3 agonist its viability decreased by 30% (165).  Taken together, these results suggest 
that EP3 expression confers a growth disadvantage to tumor cells and may play a 
protective role against cancer progression. 
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The following aim examines the distinct contribution the murine EP3 variants 
may have on tumor cell growth in vitro and in vivo in order to explore their therapeutic 
potential. Based on the findings that all three variants are downregulated or absent in 
cancer (165, 166, 168), reduced viability is observed in treated EP3-expressing cancer 
cells (165) and enhanced incidence of colon carcinomas is evident in mice deficient for 
EP3 (165), it is conceivable that restoring EP3 expression in tumor cells will suppress 
growth in vitro and reduce their tumorigenic potential in vivo.   In order to test this 
hypothesis, we expressed each receptor variant in HCT116 cells, a human colon cancer 
cell line expressing no detectable levels of endogenous EP3 (165) and HEK293 cells, 
since they are tumorigenic in vivo (175) and are commonly utilized to study prostanoid 
receptor signaling (151, 176-179).  These cells were examined for their ability to 
proliferate, signal and undergo morphological change.    
 
Results 
 
Activation of the mEP3 receptor variants reduces proliferation in vitro 
 
While EP1, EP2 and EP4 receptor signaling have all been implicated in 
tumorigenesis in different rodent models (154-156),  EP3 receptor deletion has no impact 
on early stages of tumorigenesis but may play a protective role in later stages (154, 156). 
In contast, EP3 has been implicated in tumor-associated angiogenesis in sarcoma-180 and 
sponge implantation models (167).  In order to evaluate the role the mEP3 receptor 
variants may have on cell growth we analyzed the mEP3 receptor variants for 
proliferation. HEK293 cells stably expressing mEP3 receptor variants exhibit a 30-40%  
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Figure 13. Activation of the mEP3 receptor variants reduces proliferation in vitro and this inhibitory 
effect is mediated by Rho in HEK293 cells.  (A).  [3H]Thymidine incorporation on vector-transfected and 
mEP3-expressing HEK293 cells treated with vehicle, MB28767 (MB), sulprostone (Sulp) or butaprost 
(Buta) was evaluated as described under Materials and Methods.  (B) 3H-thymidine incorporation assay on 
vector-transfected and mEP3-expressing HEK293 cells incubated in the presence or absence of 10 µM Y-
27632 and 0.1 µM MB28767 (MB) was evaluated as described under Materials and Methods. The bars and 
errors represent the mean +/- S.D. of a representative experiment performed in quadruplicates    (*) 
indicates significant differences (p<0.05) between vehicle and MB-treated cells.  (**) indicates significant 
differences (p<0.05) between MB- and MB+Y-27632 treated cells.  
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68 
reduction in growth when treated with either the EP3 selective agonists, MB28767 or 
sulprostone, compared to vector treated or untreated cells (Figure 13A).In contrast, 
butaprost did not alter proliferation compared to untreated cells, suggesting the cell 
growth inhibition observed is specific to the EP3 receptor and activation. 
 
The inhibitory effect of mEP3 receptor activation in vitro is mediated by Rho in 
HEK293 cells 
To determine whether Rho is also involved in the EP3-mediated cell growth 
inhibition as observed with the morphological change (Figure 10), the effect of the Rho 
kinase inhibitor Y-27632 was determined on proliferation in vitro.  As shown in Figure 
13B Y-27632 reversed the mEP3-mediated cell growth inhibition, and this effect was 
independent of the mEP3 variant expressed. Thus, these results suggest the EP3-induced 
reduction in cell growth and changes in morphology observed in vitro are both mediated 
by Rho. 
 
The mEP3 receptor variants inhibit tumor cell growth of HEK293 cells in vivo 
 
In order to confirm in vivo the protective role of the mEP3 receptor variants seen 
in vitro, we injected 15 male athymic/nude mice with 106 HEK293 cells. We found that 
vector transfected HEK293 cells form tumors more readily than mEP3 receptor variant-
expressing cells (13/15 Vector; 1/15 EP3α; 5/15 EP3β; 3/15 EP3γ) (Figure 14A). 
Further, the tumors isolated from vector-transfected HEK293 cells were larger than those 
derived from mEP3 receptor variant-expressing cells. Tumors were analyzed for mEP3 
receptor variant expression using the anti-myc antibody (Figure 14B). 
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Figure 14. The mEP3 receptor variants inhibit tumor cell growth in HEK293 cells in vivo.  (B)  
HEK293 cells stably expressing mEP3 receptor variants exhibit reduced tumor growth 35 days post-s.c. 
injection of 0.2 ml of 1 x 106 trypsinized cells in nude male mice compared to vector control.  Volume was 
determined according to the equation (V = [L x W2] x 0.5, where V = volume, L = length, and W = width.  
(C)  Frozen sections of mEP3α, mEP3β, mEP3γ (shown) receptor tumors isolated from s.c.-injected nude 
mice were stained with anti-myc antibody to confirm the expression of the mEP3 receptor variants. DAPI 
staining was performed to visualize cell nuclei.  
 
 
 
 
 
 
 
 
 
 
0
500
1000
1500
2000
2500
3000
3500
4000
Vector mEP3β mEP3γmEP3α
T
um
or
 v
ol
um
e 
(m
m
3 )
4500A
p<0.05
p<0.05
p<0.05
m
yc
D
A
PI
Vector mEP3γB
T
um
or
 v
ol
um
e 
(m
m
3 )
T
um
or
 v
ol
um
e 
(m
m
3 )
m
yc
D
A
PI
70 
All mEP3 variant HEK293 tumors exhibited positive staining for myc (mEP3γ shown) 
while vector HEK293 tumors were negative for myc staining, indicating HEK293 cells 
stably transfected with mEP3 receptor variants do not downregulate expression during 
tumor formation. Together these results demonstrate the mEP3 receptor variants in 
HEK293 cells induce growth suppression evident both in vitro and in vivo. 
 
EP3 receptor variant signalling activates Rho and enhances cell-cell contact in 
human colon cancer cells 
 
Thus far, we have demonstrated that PGE2 via the EP3 receptor activates the G12-
Rho pathway causing a morphological change which enhances cell-cell contact and 
reduced cell proliferation in HEK293 cells (Figures 12 & 13).  We next sought to 
investigate the role of the mEP3 receptor variants in a human colon cancer cell line 
(HCT116) rather than HEK293 cells in order to confirm EP3 signaling can activate Rho 
and cause a morphological change in a more pathophysiologically relevant cell line.  As 
with the HEK293 cells, HCT116 cells were transfected, selected and sorted for 
comparable cell-surface expression of the mEP3 receptor variants by flow cytometry 
(Figure 15A).  We then evaluated the effect of mEP3 receptor variant activation on 
RhoA GTPase (Figure 15B). HCT116 cells expressing variants (mEP3γ shown) and 
vector were stimulated with MB28767 for 15 minutes and the results demonstrate all 
three mEP3 receptor variants can induce a robust increase in RhoA activity (mEP3γ 
shown). Similar results were obtained with a second human colon cancer celline, SW480 
(Figure 15B).  These results confirm mEP3 signaling via Rho is not cell-type specific. 
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Next we examined the ability of selective EP3 agonists to induce a morphological 
change in vector or mEP3 variant expressing HCT116 cells.  All three mEP3 receptor 
variants expressed in HCT116 cells formed cell clusters with increased cell-cell contact 
within four hours of MB28767 stimulation as seen in Figure 15C by staining with 
rhodamine-phalloidin for the actin cytoskeleton and anti-ZO-1 for tight junctions.  In 
contrast vector and untreated HCT116 cells remained well dispersed and exhibited 
punctuate ZO-1 staining (Figure 15C) confirming the morphological change is ligand-
dependent. The time course of EP3-induced clustering was similar for the three variants. 
Similar results were obtained with the second human colon cancer cell line, SW480 
expressing mEP3γ and its vector counterpart (Figure 15D) and using native ligand, PGE2 
(not shown). These results demonstrate human colon cancer cells with EP3 expression 
restored display a morphological change with EP3 stimulation characterized by enhanced 
cell-cell contact indicating EP3-induced Rho activation and morphological change are not 
cell-type specific but importantly, physiologically relevant. 
 
Activation of the mEP3 receptor variants inhibits human colon cancer cell growth in vitro 
and in vivo 
 
Previous studies have shown the EP3 receptor to be downregulated or absent in 
carcinomas of the colon and breast (165, 166).  It has been reported HCT116 colon 
cancer cells to express EP1, EP2 and EP4 but no detectable EP3 (165) indicating the lack 
of EP3 expression in tumor cells may confer a proliferative advantage. To test this 
hypothesis we analyzed vector and mEP3 variant HCT116 cells for proliferation 
following stimulation with MB28767, sulprostone or butaprost.  As shown in Figure  
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Figure 15. EP3 receptor variant signaling activates Rho and enhances cell-cell contact in human 
colon cancer cells.  (A) Flow cytometry of stably transfected HCT116 cells with mEP3 receptor variants 
labeled with anti-myc antibody.  mEP3 receptor expression is displayed by a shift in mean fluorescent 
intensity compared to vector-transfected HCT116 cells.  The result shown is representative of three 
independent experiments.  (B) Rho pulldown assay performed on cells lysates of serum starved cells treated 
with vehicle or 0.1 μM MB28767 for 15 minutes.  Bound GTP-Rho was detected by immunoblotting with 
anti-Rho antibody (top). Total cell lysates were used to detect the levels of total Rho (bottom). (C& D) 
Vector-transfected and mEP3-expressing HCT116 and SW480 cells were treated with vehicle or 0.1 μM 
MB28767.  After four hours, the cells were stained with rhodamine-phalloidin (HCT116 only) and anti-
ZO-1 antibody to visualize the cytoskeleton and tight junctions, respectively.   
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16A, a 40-50% reduction in proliferation was observed only when cells were treated with 
the EP3 selective agonists but not with the EP2 agonist, butaprost.   These results confirm 
data obtained with HEK293 cells and suggest the effects on proliferation by the mEP3 
variants are not cell-type specific.   
 
To further test the hypothesis that the EP3 receptor can suppress growth of colon 
cancer cells, we injected mEP3 variant expressing HCT116 cells in vivo. We injected 6 
male athymic/nude mice with 106 vector transfected colon cancer cells and 8 male 
athymic/nude mice with 106 variant expressing colon cancer cells. Although nearly all 
mice formed tumors within a month (6/6 Vector; 8/8 EP3α; 7/8 EP3β; 8/8 EP3γ) (Figure 
16B), the tumors isolated from vector HCT116-injected mice were larger than those 
tumors isolated from mEP3 receptor variant HCT116-injected mice. Tumors were 
analyzed for mEP3 receptor variant expression using the anti-myc antibody (Figure 
16C). All mEP3 expressing HCT116 tumors exhibited positive staining for myc (mEP3γ 
shown for simplicity) while empty vector tumors were negative for myc staining, 
indicating HCT116 cells stably transfected with mEP3 receptor variants do not 
downregulate expression during tumor formation. Collectively these results indicate 
human colon cancer cells with either mEP3α, mEP3β or mEP3γ receptor expression 
restored can suppress growth evident both in vitro and in vivo. 
 
Conclusions 
 Although EP3 is widely expressed throughout the body, expression in 
tumors is found downregulated or absent (165, 166, 168) but the role of the mouse EP3  
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Figure 16. Activation of the mEP3 receptor variants inhibits human colon cancer cell growth in vitro 
and in vivo.  (A)  3H-Thymidine incorporation assay on HCT116 colon tumor cells stably expressing mEP3 
receptor variants pulsed for 48 h with [3H]thymidine (1 µCi/well) with 0.1 µM of MB-28767, sulprostone, 
butaprost or vehicle.  These data are representative of three independent experiments performed in 
quadruplicates. *p < 0.05  (B) 1x106 vector-transfected and mEP3-expressing HCT116 cells were injected 
subcutaneously into nude mice (n=10/cell type).   Thirty-five days later the mice were sacrificed and tumor 
volume was evaluated as described under Materials and Methods. Open squares represent the volume of 
single tumors, while the bars represent the mean.  (C) Frozen sections of tumors derived from the tumors 
indicated (only mEP3γ shown) were stained with anti-myc antibody to confirm the in vivo expression of the 
mEP3 receptor variants. 
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receptor variants α, β and γ on tumor cell function is yet unknown.  By expressing all 
three variants in HEK293 cells, which do not demonstrate any measureable membrane 
associated EP3 receptor (Figure 5A & 5C), we have demonstrated all three variants 
reduce proliferation in vitro and that this growth inhibitory effect is mediated by Rho. 
Furthermore, as HEK293 cells are tumorigenic in nude mice, we examined the 
contribution of each mEP3 variant on tumor growth in vivo and showed all three variants 
led to the formation of fewer and smaller tumors compared to vector HEK293 cells.   
 
 Although HEK293 cells are commonly used to investigate prostanoid receptor 
function (151, 176-179), the significance of our aforementioned results in this cell line 
can be addressed by investigating these effects in a more physiologically relevant cell 
line.  Since EPs have been well studied in intestinal tumorigenesis  (146-148, 150-152, 
154, 155) and EP3 receptor expression is down-regulated in human colon cancer cells 
(165), we chose to restore mEP3 receptor variant expression in two such cell lines which 
lack detectable EP3 and investigate their effect on tumor growth.  First we demonstrate 
mEP3 receptor variant signaling can activate Rho in HCT116 and SW480 cells as well as 
enhance cell-cell contact similar to results observed in HEK293 cells. Activation of the 
three variants increased Rho GTP levels robustly in human colon cancer cells and the 
change in morphology was similar for all three variants where cells clustered and 
increased their cell-cell contact levels.  Lastly and most importantly, all three variants led 
to reduced tumor cell growth in vitro and in vivo indicating the results observed in 
HEK293 cells are physiologically relevant and not cell-type specific. 
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CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
Overview 
Despite the vast amount of research performed on EP receptors, little is known on 
the physiological or pathological effects of the EP3 splice variants and their signal 
transduction pathways. Overall genetic or pharmacological cancer models have shown 
the EP3 receptor to not play a direct role in tumor carcinogenesis (146, 150, 153-155). 
Recently however a number of studies have suggested the EP3 receptor may have a 
tumor suppressive role as its expression in tumor cells is found absent or downregulated 
and the loss of the EP3 receptor leads to increased colon carcinoma following chemical 
treatment (165, 166).  Thus far, no study has examined the role of the EP3 variants on 
tumor cell function.  One of the major goals of this thesis was to examine the molecular 
mechanisms by which the EP3 variants control specific tumor cell functions.  We focused 
on the role of the mouse EP3 variants as they are highly homologous to the human 
variants (98) and unique to exist with three alternatively spliced cytoplasmic tails.  These 
three C-terminal tails have the potential to signal uniquely and cause alternative effects 
upon stimulation with their common native ligand, PGE2.  We hypothesized the three 
mouse EP3 variants would have a suppressive effect on tumor cell growth.  We first 
characterized the three variants for signaling and morphological differences in HEK293 
cells.  Our results indicate the three variants signal similarly where intracellular calcium 
is mobilized and the ERK and Rho pathways are activated with selective agonist 
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stimulation.  This suggests the differences in amino acid sequences between the three 
variants’ C-terminal tails do not influence signaling of these pathways.  Additionally, we 
show activation of all three mouse variants causes a morphological change which 
enhances cell-cell contact and causes cells to appear less fibroblast-like and more 
epithelial-like.  This suggests the mEP3 variants do not promote an invasive phenotype, 
in contrast, they promote tighter junctions thus reducing the tumorigenic potential of 
cells.  Furthermore, we show the morphological change is mediated by Rho and most 
likely involves the G12 G-protein.  Lastly, we examined the role of the mouse C-terminal 
tails to influence agonist-induced internalization of the EP3 receptor.  Our results indicate 
the C-terminal tails are important in determining the level of EP3 expression at the cell 
surface.  Further investigation is needed in order delineate the regulatory and signaling 
mechanisms involved in agonist-internalization of the EP3 variants. 
 
In addition to examining the role of mEP3 receptors in HEK293 cells, we 
examined the functional role of each variant on tumor cell growth in vitro and in vivo.  In 
contrast to EP1, EP2 and EP4, EP3 receptor expression is decreased in colon cancer in 
mice, rats and humans when compared to normal mucosa (165). Deletion of the EP3 
receptor does not alter early stages of colon cancer progression, namely aberrant crypt 
foci development, whereas EP1, EP2, and EP4 receptors are involved in small intestinal 
polyp formation (154-156).  However, in contrast to the other EP receptors, an increase in 
carcinogen-induced colon carcinoma was found in EP3-null mice, suggesting EP3 may 
impact later stages of colon carcinogenesis (165). Furthermore, only one of eleven colon 
cancer cell lines was shown to express EP3 and when that cell line was treated with an 
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EP3 agonist its viability decreased by 30% (165). In order to investigate the role of the 
three mEP3 variants on tumor cell function we chose to restore EP3 expression in 
HCT116 cells, a human colon cancer cell line shown to lack both EP3 (165) and COX-2 
(169) expression.  We demonstrate in both HCT116 and HEK293 cells that the mEP3 
variants reduce tumor cell growth in vitro and in vivo.  We further evaluate the 
mechanism of this inhibitory growth effect by mEP3 in HEK293 cells and show Rho to 
mediate proliferation in vitro.  Interestingly, we observed a morphological change in 
HCT116 tumor cells similar to what was observed in HEK293 cells characterized by 
enhanced ZO-1 staining, thus cell-cell contact. Furthermore, we analyzed HCT116 cells 
for EP3-induced Rho activation and found all three variants to increase levels of Rho 
GTP within 15 minutes of stimulation by selective EP3 agonist.  These results suggest the 
mechanism for the EP3-induced morphological change and growth inhibition is via Rho 
and thus not cell-type specific. 
 
Discussion and Future Directions 
Activation of the mEP3 receptor variants induces a morphological change mediated by a 
G12-RhoA pathway  
 
 Despite the vast amount of research performed on the EP3 receptor, little is 
known on the signaling mechanisms and physiological significance of the C-terminal 
splice variants.  Functional differences among the murine splice variants have been 
reported, including coupling to different signal transduction pathways (158), different 
sensitivities to agonist-induced desensitization(180), different extents of constitutive 
activity(164), different intracellular trafficking patterns(181), and different agonist-
induced internalization patterns(162).  We have addressed the fundamental question as to 
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what is the functional significance of these alternative splice variants, by examining the 
distinct role of the murine EP3 receptor variants in tumor cell function both in vitro and 
in vivo.  We provide evidence that all three variants promote intracellular calcium 
mobilization in a similar dose- and time-dependent manner as described by others (170).  
Moreover, we show the three variants have indistinguishable effects on tumor cell 
function: they each can activate ERK and Rho, and cause a long-lasting morphological 
change characterized by a marked increase in cell-cell contact mediated by a G12-Rho 
pathway and reduce cell growth in vivo and in vitro.  Therefore, in the context of tumor 
cell function, all three mEP3 variants can similarly reduce tumorigenic potential. 
 
We further investigated the morphological change for reverse epithelial-to-
mesenchymal transition since activation of all three variants caused a morphological 
change characterized by enhanced cell-cell contact. We observed and show in Figure 8B 
by immunofluorescent staining for ZO-1, enhanced tight junctions with EP3 activation. 
EMT is an essential developmental process by which cells of epithelial origin lose 
epithelial characteristics and polarity, and acquire a mesenchymal phenotype with 
increased migratory behavior (182-186). Thus, EMT is characterized by loss of 
intercellular adhesion (E-cadherin and occludins); down-regulation of epithelial makers 
(cytokeratins); up-regulation of mesenchymal markers [vimentin, fibroblast-specific 
protein (FSP) and smooth muscle actin (SMA)]; acquisition of fibroblast-like (spindle) 
morphology with cytoskeleton reorganization; and increase in motility, invasiveness, and 
metastasic capabilities (182-186). In addition, the process known as "cadherin switching" 
(down-regulation of E-cadherin and up-regulation of mesenchymal cadherins such as N-
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cadherin or cadherin-11) and the accumulation of β-catenin have also been associated 
with EMT (183, 184). We therefore looked by immunofluorescence and western blot 
analysis for enhanced E-cadherin and β-catenin and reduced FSP and SNAIL, a 
transcriptional repressor of E-cadherin.  Similar to ZO-1, we observed enhanced staining 
of E-cadherin and β-catenin at the cell-surface by immunofluorescence but not by 
western blot indicating they are not upregulated rather localizing to the cell-surface with 
EP3 activation. Results of FSP and SNAIL were inconclusive due to problems with the 
FSP antibody and inconsistent western blot results with anti-SNAIL antibodies. Further 
analysis can be performed looking at cell cycle and proliferation proteins (cyclins, p27, 
p21, survivin, and Ki67). 
 
Among classical second messenger pathways, the EP3 receptor is coupled to 
adenylate cyclase inhibition through Gi (163, 164), however the morphological change 
induced by activation of this receptor in HEK293 cells was not suppressed by pertussis 
toxin (PT) treatment, indicating that its action was mediated by PT-insensitive 
heterotrimeric G protein. The EP3 receptor has been shown to activate Rho in various 
cell lines and constitutively active G12 and G13 can activate Rho (119, 120, 174), 
suggesting that one or both of these G proteins may signal to Rho via EP3.  Our in vitro 
data strongly suggests that all three murine variants mediate Rho activation via G12.  Our 
data demonstrates overexpression of dominant negative G12, but not G13 prevents the 
EP3-induced enhanced cell-cell contact.  Although dominant negative studies are valid 
and informative, they present some limitations. Since dominant negative G13 could not 
prevent EP3-mediated cell-cell contact, we can suggest but not unequivocally prove that 
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G13 is not involved in EP3-mediated functions.  Presently, the dominant negative 
approach represents one of the best and most acceptable methods of distinguishing 
between G12- versus G13-mediated activity.  For instance, G12 and/or G13 coupling have 
been identified using this method for GPCR receptors such the α1-adrenoceptor, the 
vasopressin V1a receptor and the 5-HT2C receptor (187), in addition to our present study 
for the mEP3 receptor variants.  Further investigations utilizing short-interfering RNA 
(siRNA) may corroborate our results and further confirm the mechanism of the EP3-
induced morphological change.  By silencing specific Gα subunits, we can downregulate 
and abrogate G12 and/or G13 signaling and potentially prevent the morphological change 
in the presence of selective EP3 agonist.  Further studies for this project may also include 
identifying the link between activation of EP3-G12 and the subsequent Rho activation 
mediating the changes observed in morphology by EP3 activation.  Recently, a group of 
Rho-specific guanine nucleotide exchange factors (RhoGEFs) has been identified which 
interact with the activated α-subunit of G12/G13 and can couple GPCRs to Rho activation. 
Currently, this group of RhoGEF-proteins comprises three members, p115RhoGEF/Lsc, 
PDZRhoGEF and Leukaemia-associated Rho guanine nucleotide exchange factor 
(LARG)(188-190).  Recently the siRNA technique was found to be a potent targeting 
method against RhoGEFs. Also, the three siRNAs targeting LARG, PDZ-RhoGEF, and 
p115-RhoGEF are able to discriminate the closely related sequences within this RhoGEF 
gene family (191).  With these siRNA sequences we could further clarify the pathway 
involved in EP3-mediated Rho activation and subsequent changes in morphology. 
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The mEP3 receptor variants suppress tumor cell growth in vitro and in vivo 
 
 Several studies exploring the role of EP receptor subtypes using genetic deletion 
or a pharmacologic approach have consistently shown the EP3 receptor to not play role 
on tumorigenesis (154-156).  In this context, deficiency in EP3 had no effect on aberrant 
crypt foci development, putative precursors of colon cancer.  In contrast, an increase in 
azoxymethane-induced colon carcinoma was found in EP3 deficient mice, suggesting 
EP3 may impact late stages of colon carcinogenesis (165).  In agreement with this 
hypothesis, examination of EP3 mRNA expression in mammary and colon tumors 
showed a marked reduction in this receptor transcript levels compared to normal mucosa 
(165, 166). Moreover, EP3 expression was detected in only one of eleven colon cancer 
cell lines tested and treatment of that one cell line with an EP3 agonist decreased viability 
by 30%(165).  Our in vivo findings that over-expression of mEP3 variants decreases the 
tumorigenic potential of two different tumor cell lines, suggest that EP3 may play a 
suppressive role in tumor development and its downregulation in tumor cells is 
advantageous for cancer progression. 
 
The small GTPase Rho plays an important role in processes such as cytoskeletal 
rearrangement, migration and cell growth (192-195).  Rho can be activated by different 
receptors including extracellular matrix receptors, growth factor receptors and prostanoid 
receptors.  Thus far, only the mouse EP3 α and β variants have been shown to activate 
Rho and mediate stress fiber formation (120).  In this study we report α, β and γ variants 
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can similarly activate Rho in HEK293 cells and their activation is linked to enhanced 
cell-cell contact and growth inhibition.   
 
This is the first study to characterize all three variants in HEK293 cells for Rho 
activation and since all three variants were found to increase Rho-GTP with EP3 agonist 
treatment we investigated further the role of the mEP3 variant-induced Rho activation on 
cell morphology and proliferation.  Interestingly, these findings demonstrate Rho to have 
an inverse correlation with cell proliferation; with EP3-induced Rho activation reducing 
tumor cell growth; and Rho-inhibition restoring tumor cell proliferation.  In contrast, 
others have shown Rho is activated in many tumors types and it plays a positive role in 
tumorigenesis and metastasis by enhancing cell migration, proliferation, as well as 
protease synthesis and consequent matrix remodeling (196, 197).   The marked increase 
in cell-cell contact and the mesenchymal-to-epithelial morphological transition observed 
with EP3 activation results in contact inhibition and cell cycle arrest.  A possible 
explanation for our finding is that EP3-mediated Rho activation leads to increased cell-
cell contact, resulting in contact inhibition and cell growth arrest. Contact inhibition is a 
well known mechanism of controlling cell growth and is thought to be mediated at least 
in part by blocking the growth factor and integrin-mediated stimuli required for cells to 
proliferate (198). Furthermore it has been recently shown that Rho activation is necessary 
to establish complete cell-cell adhesion (199). Thus, as we show that EP3 can induce long 
lasting cell-cell contact, it is plausible this is a major mechanism whereby this receptor 
decreases cell proliferation in vitro and tumorigenesis in vivo. For this reason Rho 
signaling may not be directly anti-proliferative but indirectly causing the morphological 
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change which prevents proliferation (Figure 17). The fact that the EP3-induced 
morphological change is long lasting (Figure 9B), even after ligand withdrawl, supports 
our hypothesis that the Rho-mediated growth inhibitory effects observed upon EP3 
activation is most likely the result of prolonged contact inhibition.  
 
In agreement with this possibility, our data demonstrates that restoring and 
activating the EP3 receptor in tumor cells with a selective agonist is clinically favorable 
as it was able to fully restore epithelial morphology and reduce growth of tumor cells.  
The clinical potential of selective EP3 agonists compared with selective inhibitors of 
COX-2 or with traditional NSAIDs, such as aspirin would seem more favorable knowing 
the complex and adverse effects of inhibiting multiple prostanoids simultaneously, 
prostanoids that are known to play a protective effect in some settings.  However, EP3 
expression is downregulated or absent in tumors of the colon and mammary and the 
mechanism is yet unclear.  Hypermethylation of CpG islands in promoter regions is 
known to cause silencing of genes in various human cancers (200, 201).  Although 
hypermethylation of the EP3 gene has not been reported, Shoji, et. al. found  DNA 
sequences in the promoter region and exon 1 of the human EP3 gene are GC rich 
(Genbank AL031429) and demethylation of five human colon cancer cell lines restored 
EP3 expression (165).  These findings suggest that the DNA sequence of the EP3 
receptor may be methylated however further investigation is needed to confirm 
hypermethylation of the EP3 gene occurs and how this is regulated.   
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Figure 17.  Regulation of cell growth and morphology by the mEP3 receptor variants.  Schematic 
model of how the mEP3 receptor variants may regulate cell morphology and growth. Activation of the 
mEP3 receptor variants leads to activation of ERK, calcium mobilization and activation of the G protein 
alpha subunit G12.  G12 leads to activation of RhoA with consequent increase in cell-cell contact and 
reduced cell growth.   
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While our results demonstrate selective EP3 agonists delivered to the tumor cells 
may be a favorable clinical therapy for cancer, it is important to remember the influence 
the host microenvironment has on tumor progression.  Prostaglandins are important  
regulators of tumor-host communications.  A recent study in EP3 null mice revealed 
stromal and/or tumor cells release PGE2 into the tumor microenvironment, which acts on 
stromal cells that contain EP3 receptors to induce the production of pro-angiogenic 
factors and consequent angiogenesis (167).  This indicates that without EP3 expression 
on the tumor cells, there is no significant anti-proliferative advantage to administering 
selective EP3 agonists.  Signaling in stromal cells by EP3 receptors has revealed 
induction of VEGF which has pro-angiogenic action and facilitates tumor growth (167).  
This is the first study to implicate EP3 as having a pro-tumorigenic role.  This highlights 
the potential tissue and model specificity of EP receptor PGE2 signaling that is becoming 
apparent.  In the future, it will be important to determine whether COX-2 can modulate 
EP receptor expression and identify the precise role each receptor signaling pathway plays 
in regulating angiogenesis and tumor growth. For this reason further investigation is 
needed into the role the host EP3 receptor expression and activation may have on tumor 
progression before seriously considering the therapeutic potential of EP3 selective 
agonists.  Further studies that may elucidate the role of EP3 signaling on tumor 
progression would be to use our human colon cancer cell lines overexpressing each 
mEP3 variant and injecting these in nude mice deficient in EP3.  By injecting these cells 
either subcutaneously or orthotopically we may delineate the role of EP3 in the tumor 
versus host EP3 expression/signaling.  If we were to demonstrate restoring EP3 
expression in tumor cells can reduce tumor growth in vivo in both wildtype and EP3 
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deficient mice this would further support our hypothesis that EP3 acts as a tumor 
suppressor in tumor cells regardless of host expression of EP3.   
 
Conclusion 
From this study, we propose new possible functions of PGE2 through the EP3 
receptor. The major goal of this thesis was to examine the mouse EP3 receptor variants α, 
β and γ on tumor cell function.  The three mouse variants of EP3 have never been 
investigated for their functional significance in tumor cells before the present study.  Our 
results demonstrated activation of the three mEP3 variants caused a Rho-mediated 
morphological change never described before characterized by enhanced cell-cell contact. 
These effects were the same for all three variant, indicating the variants’ cytoplasmic tails 
have no functional difference in respect to tumor cell morphology however we did 
observe differential cell surface localization depending on the variant activated.  This 
suggests the C-terminal tail is important in intracellular trafficking and agonist-induced 
internalization.  Interestingly, EP3 activation caused a morphological change that was 
long-lasting even after the removal of agonist which is promising for long-term anti-
neoplastic effects by selective EP3 agonists.  
 
In addition we have demonstrated a novel mechanism for the EP3-induced 
morphological change.  Our results indicate EP3 signaling enhances cell-cell contact via 
the small GTPase G12-Rho pathway.  In contrast to the published findings that Rho plays 
a positive role in tumorigenesis, we found Rho activation to have an inverse correlation 
with proliferation.   
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In conclusion we have provided new evidence of the involvement of all three 
variants in reducing tumor cell growth in vitro and in vivo. Additionally, the effects 
demonstrated by EP3 activation was evaluated in several tumor cell lines with no 
difference observed in vitro or in vivo therefore EP3-induced growth suppression was not 
cell-specific. Again, there was no difference observed between variants on tumor growth 
suggesting the C-terminal tail has the same effect on the tumorigenic potential.  
Importantly, we and others have shown that EP3 expression is reduced or absent in tumor 
cells (165, 166, 168), this is the first study to show restoring EP3 expression in tumor 
cells can have an inhibitory effect on tumor development. 
  
 Together these studies elucidate the role of the PGE2 EP3 receptor subtype on 
tumor cell function.   Data obtained in our present studies suggest the EP3 receptor plays 
an important role in suppression of cell growth.  These results along with previous studies 
suggest its downregulation enhances carcinogenesis.  However the exact mechanism 
regulating to this decrease in EP3 expression warrants further investigation. Taken 
together, these findings provide a rationale for the development of EP3 agonists.  The 
clinical potential of selective EP3 agonists compared to selective COX-2 inhibitors or 
traditional NSAIDs is more favorable given that anti-COX therapy prevents the 
simultaneous synthesis of multiple prostanoids, some of which play a protective effect in 
many physiological and pathophysiological settings. 
 
 
 
 
89 
REFERENCES 
 
 
1. Williams, C. S., Smalley, W., and DuBois, R. N. Aspirin use and potential 
mechanisms for colorectal cancer prevention. J Clin Invest, 100: 1325-1329, 
1997. 
2. Smith, W. L., DeWitt, D. L., and Garavito, R. M. Cyclooxygenases: structural, 
cellular, and molecular biology. Annu Rev Biochem, 69: 145-182, 2000. 
3. Kujubu, D. A., Fletcher, B. S., Varnum, B. C., Lim, R. W., and Herschman, H. R. 
TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, 
encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem, 
266: 12866-12872, 1991. 
4. Smith, W. L., Garavito, R. M., and DeWitt, D. L. Prostaglandin endoperoxide H 
synthases (cyclooxygenases)-1 and -2. J Biol Chem, 271: 33157-33160, 1996. 
5. Vane, J. R., Bakhle, Y. S., and Botting, R. M. Cyclooxygenases 1 and 2. Annu 
Rev Pharmacol Toxicol, 38: 97-120, 1998. 
6. Herschman, H. R. Prostaglandin synthase 2. Biochim Biophys Acta, 1299: 125-
140, 1996. 
7. Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. Transcriptional 
regulation of human prostaglandin-endoperoxide synthase-2 gene by 
lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of 
both nuclear factor for interleukin-6 expression site and cAMP response element. 
J Biol Chem, 270: 24965-24971, 1995. 
8. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, 
E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal 
polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 
(COX-2). Cell, 87: 803-809, 1996. 
9. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., 
Haudenschild, C., Lane, T. F., and Hla, T. Overexpression of cyclooxygenase-2 is 
sufficient to induce tumorigenesis in transgenic mice. J Biol Chem, 276: 18563-
18569, 2001. 
10. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De 
Putte, L. B., and Lipsky, P. E. Cyclooxygenase in biology and disease. Faseb J, 
12: 1063-1073, 1998. 
11. Hla, T., Bishop-Bailey, D., Liu, C. H., Schaefers, H. J., and Trifan, O. C. 
Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol, 31: 551-557, 
1999. 
12. Hla, T., Ristimaki, A., Appleby, S., and Barriocanal, J. G. Cyclooxygenase gene 
expression in inflammation and angiogenesis. Ann N Y Acad Sci, 696: 197-204, 
1993. 
13. Prescott, S. M. and Fitzpatrick, F. A. Cyclooxygenase-2 and carcinogenesis. 
Biochim Biophys Acta, 1470: M69-78, 2000. 
14. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl 
Cancer Inst, 90: 1529-1536, 1998. 
15. Jacoby, R. F., Cole, C. E., Tutsch, K., Newton, M. A., Kelloff, G., Hawk, E. T., 
and Lubet, R. A. Chemopreventive efficacy of combined piroxicam and 
90 
difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and 
selective toxicity against Apc mutant embryos. Cancer Res, 60: 1864-1870, 2000. 
16. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive 
activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon 
carcinogenesis. Cancer Res, 58: 409-412, 1998. 
17. Oshima, M., Murai, N., Kargman, S., Arguello, M., Luk, P., Kwong, E., Taketo, 
M. M., and Evans, J. F. Chemoprevention of intestinal polyposis in the 
Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer 
Res, 61: 1733-1740, 2001. 
18. Harris, R. E., Alshafie, G. A., Abou-Issa, H., and Seibert, K. Chemoprevention of 
breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res, 60: 
2101-2103, 2000. 
19. Fischer, S. M., Lo, H. H., Gordon, G. B., Seibert, K., Kelloff, G., Lubet, R. A., 
and Conti, C. J. Chemopreventive activity of celecoxib, a specific 
cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced 
skin carcinogenesis. Mol Carcinog, 25: 231-240, 1999. 
20. Grubbs, C. J., Lubet, R. A., Koki, A. T., Leahy, K. M., Masferrer, J. L., Steele, V. 
E., Kelloff, G. J., Hill, D. L., and Seibert, K. Celecoxib inhibits N-butyl-N-(4-
hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 
mice and female Fischer-344 rats. Cancer Res, 60: 5599-5602, 2000. 
21. Rioux, N. and Castonguay, A. Prevention of NNK-induced lung tumorigenesis in 
A/J mice by acetylsalicylic acid and NS-398. Cancer Res, 58: 5354-5360, 1998. 
22. Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y., 
Tsutsumi, N., Sugimura, M., and Konishi, Y. Increased expression of 
cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue 
carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. 
Cancer Res, 61: 1451-1456, 2001. 
23. Zhang, X., Morham, S. G., Langenbach, R., and Young, D. A. Malignant 
transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs 
(NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med, 190: 451-459, 
1999. 
24. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., and Thun, M. J. Cancer 
statistics, 2007. CA Cancer J Clin, 57: 43-66, 2007. 
25. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, 
E. J., and Thun, M. J. Cancer statistics, 2005. CA Cancer J Clin, 55: 10-30, 2005. 
26. Fearon, E. R. and Vogelstein, B. A genetic model for colorectal tumorigenesis. 
Cell, 61: 759-767, 1990. 
27. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., 
Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and 
Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal 
cancer. Irinotecan Study Group. N Engl J Med, 343: 905-914, 2000. 
28. Waddell, W. R. and Loughry, R. W. Sulindac for polyposis of the colon. J Surg 
Oncol, 24: 83-87, 1983. 
29. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced 
risk of fatal colon cancer. N Engl J Med, 325: 1593-1596, 1991. 
91 
30. Sandler, R. S., Halabi, S., Baron, J. A., Budinger, S., Paskett, E., Keresztes, R., 
Petrelli, N., Pipas, J. M., Karp, D. D., Loprinzi, C. L., Steinbach, G., and 
Schilsky, R. A randomized trial of aspirin to prevent colorectal adenomas in 
patients with previous colorectal cancer. N Engl J Med, 348: 883-890, 2003. 
31. Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., 
McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., Snover, D. 
C., Church, T. R., Allen, J. I., Beach, M., Beck, G. J., Bond, J. H., Byers, T., 
Greenberg, E. R., Mandel, J. S., Marcon, N., Mott, L. A., Pearson, L., Saibil, F., 
and van Stolk, R. U. A randomized trial of aspirin to prevent colorectal adenomas. 
N Engl J Med, 348: 891-899, 2003. 
32. Pollard, M. and Luckert, P. H. Effect of indomethacin on intestinal tumors 
induced in rats by the acetate derivative of dimethylnitrosamine. Science, 214: 
558-559, 1981. 
33. Pollard, M. and Luckert, P. H. Prevention and treatment of primary intestinal 
tumors in rats by piroxicam. Cancer Res, 49: 6471-6473, 1989. 
34. Giovannucci, E., Egan, K. M., Hunter, D. J., Stampfer, M. J., Colditz, G. A., 
Willett, W. C., and Speizer, F. E. Aspirin and the risk of colorectal cancer in 
women. N Engl J Med, 333: 609-614, 1995. 
35. Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., and 
Willett, W. C. Aspirin use and the risk for colorectal cancer and adenoma in male 
health professionals. Ann Intern Med, 121: 241-246, 1994. 
36. Waddell, W. R., Ganser, G. F., Cerise, E. J., and Loughry, R. W. Sulindac for 
polyposis of the colon. Am J Surg, 157: 175-179, 1989. 
37. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., 
Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of 
colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N 
Engl J Med, 328: 1313-1316, 1993. 
38. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., and 
DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human 
colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 
1994. 
39. Elder, D. J., Baker, J. A., Banu, N. A., Moorghen, M., and Paraskeva, C. Human 
colorectal adenomas demonstrate a size-dependent increase in epithelial 
cyclooxygenase-2 expression. J Pathol, 198: 428-434, 2002. 
40. Hao, X., Bishop, A. E., Wallace, M., Wang, H., Willcocks, T. C., Maclouf, J., 
Polak, J. M., Knight, S., and Talbot, I. C. Early expression of cyclo-oxygenase-2 
during sporadic colorectal carcinogenesis. J Pathol, 187: 295-301, 1999. 
41. Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., 
Zimmerman, G. A., White, R. L., and Prescott, S. M. Prostaglandin H synthase 2 
is expressed abnormally in human colon cancer: evidence for a transcriptional 
effect. Proc Natl Acad Sci U S A, 93: 4816-4820, 1996. 
42. Einspahr, J. G., Krouse, R. S., Yochim, J. M., Danenberg, P. V., Danenberg, K. 
D., Bhattacharyya, A. K., Martinez, M. E., and Alberts, D. S. Association 
between Cyclooxygenase expression and colorectal adenoma characteristics. 
Cancer Res, 63: 3891-3893, 2003. 
92 
43. Hasegawa, K., Ichikawa, W., Fujita, T., Ohno, R., Okusa, T., Yoshinaga, K., and 
Sugihara, K. Expression of cyclooxygenase-2 (COX-2) mRNA in human 
colorectal adenomas. Eur J Cancer, 37: 1469-1474, 2001. 
44. DuBois, R. N., Radhika, A., Reddy, B. S., and Entingh, A. J. Increased 
cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. 
Gastroenterology, 110: 1259-1262, 1996. 
45. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. 
B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in 
Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996. 
46. Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, 
C., Tiano, H. F., Morham, S. G., Smithies, O., and Langenbach, R. Genetic 
disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min 
mice. Cancer Res, 60: 4705-4708, 2000. 
47. Reddy, B. S., Hirose, Y., Lubet, R., Steele, V., Kelloff, G., Paulson, S., Seibert, 
K., and Rao, C. V. Chemoprevention of colon cancer by specific cyclooxygenase-
2 inhibitor, celecoxib, administered during different stages of carcinogenesis. 
Cancer Res, 60: 293-297, 2000. 
48. Reddy, B. S., Rao, C. V., Rivenson, A., and Kelloff, G. Inhibitory effect of aspirin 
on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14: 
1493-1497, 1993. 
49. Yoshimi, N., Shimizu, M., Matsunaga, K., Yamada, Y., Fujii, K., Hara, A., and 
Mori, H. Chemopreventive effect of N-(2-cyclohexyloxy-4-nitrophenyl)methane 
sulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, in rat colon 
carcinogenesis induced by azoxymethane. Jpn J Cancer Res, 90: 406-412, 1999. 
50. Fukutake, M., Nakatsugi, S., Isoi, T., Takahashi, M., Ohta, T., Mamiya, S., 
Taniguchi, Y., Sato, H., Fukuda, K., Sugimura, T., and Wakabayashi, K. 
Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on 
azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis, 19: 1939-
1942, 1998. 
51. Evans, J. F. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is 
chemopreventive in a mouse model of colon cancer. Am J Clin Oncol, 26: S62-
65, 2003. 
52. Jacoby, R. F., Marshall, D. J., Newton, M. A., Novakovic, K., Tutsch, K., Cole, 
C. E., Lubet, R. A., Kelloff, G. J., Verma, A., Moser, A. R., and Dove, W. F. 
Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse 
model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res, 56: 
710-714, 1996. 
53. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove, W. F., Hamilton, S. R., 
Vogelstein, B., and Kinzler, K. W. Sulindac suppresses tumorigenesis in the Min 
mouse. Carcinogenesis, 17: 1757-1760, 1996. 
54. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., 
Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., 
and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation 
are blocked by sulindac in a murine model of familial adenomatous polyposis. 
Cancer Res, 56: 2556-2560, 1996. 
93 
55. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for 
aspirin-like drugs. Nat New Biol, 231: 232-235, 1971. 
56. Mead, J., Alfin-Slater, RB, Howton, DR and Popjak, G. Prostaglandins, 
thromboxanes and prostacyclin. In: J. Mead (ed.), Lipids: Chemistry, 
Biochemistry and Nutrition, pp. 149-216. New York: Plenum Press, 1986. 
57. Burr GO, B. M. On the nature and role of the fatty acids essential in nutrition. J. 
Biol. Chem., 86: 587-621, 1930. 
58. Euler, U. An adrenal-like action in extracts from prostatic and related glands. J. 
Physiol., 81: 102-112, 1934. 
59. Kurzrok R, L. C. Biochemical studies on human semen. II. Action of semen on 
human uterus. Proc. Soc. Exp. Biol. Med., 28: 268-272, 1930. 
60. Bergstroem, S., Danielsson, H., and Samuelsson, B. The Enzymatic Formation of 
Prostaglandin E2 from Arachidonic Acid Prostaglandins and Related Factors 32. 
Biochim Biophys Acta, 90: 207-210, 1964. 
61. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. 
Science, 294: 1871-1875, 2001. 
62. Muller, R. Crosstalk of oncogenic and prostanoid signaling pathways. J Cancer 
Res Clin Oncol, 130: 429-444, 2004. 
63. Wallace, J. L. Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin 
North Am, 21: 631-641, 1992. 
64. Sugimoto, Y. and Narumiya, S. Prostaglandin E receptors. J Biol Chem, 282: 
11613-11617, 2007. 
65. Samuelsson, B. Isolation and Identification of Prostaglandins from Human 
Seminal Plasma. 18. Prostaglandins and Related Factors. J Biol Chem, 238: 3229-
3234, 1963. 
66. Woo, S. K., Roszkowski, P., Waterbury, L. D., and Garay, G. L. Gastric mucosal 
binding studies with enprostil: a potent anti-ulcer prostaglandin. Prostaglandins, 
32: 243-257, 1986. 
67. Breyer, M. D. and Breyer, R. M. G protein-coupled prostanoid receptors and the 
kidney. Annu Rev Physiol, 63: 579-605, 2001. 
68. Kennedy, C. R., Zhang, Y., Brandon, S., Guan, Y., Coffee, K., Funk, C. D., 
Magnuson, M. A., Oates, J. A., Breyer, M. D., and Breyer, R. M. Salt-sensitive 
hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. 
Nat Med, 5: 217-220, 1999. 
69. Davis, R. J., Murdoch, C. E., Ali, M., Purbrick, S., Ravid, R., Baxter, G. S., 
Tilford, N., Sheldrick, R. L., Clark, K. L., and Coleman, R. A. EP4 prostanoid 
receptor-mediated vasodilatation of human middle cerebral arteries. Br J 
Pharmacol, 141: 580-585, 2004. 
70. Walch, L., de Montpreville, V., Brink, C., and Norel, X. Prostanoid EP(1)- and 
TP-receptors involved in the contraction of human pulmonary veins. Br J 
Pharmacol, 134: 1671-1678, 2001. 
71. Hata, A. N. and Breyer, R. M. Pharmacology and signaling of prostaglandin 
receptors: multiple roles in inflammation and immune modulation. Pharmacol 
Ther, 103: 147-166, 2004. 
94 
72. Kurie, J. M. and Dubois, R. N. Prostaglandin E synthase: another enzyme in the 
cyclooxygenase pathway driving epithelial cancer? Clin Cancer Res, 7: 2608-
2610, 2001. 
73. Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., and Tarnawski, A. S. 
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting 
colon cancer growth and gastrointestinal hypertrophy. Nat Med, 8: 289-293, 
2002. 
74. Rigas, B., Goldman, I. S., and Levine, L. Altered eicosanoid levels in human 
colon cancer. J Lab Clin Med, 122: 518-523, 1993. 
75. Uefuji, K., Ichikura, T., and Mochizuki, H. Cyclooxygenase-2 expression is 
related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. 
Clin Cancer Res, 6: 135-138, 2000. 
76. Rolland, P. H., Martin, P. M., Jacquemier, J., Rolland, A. M., and Toga, M. 
Prostaglandin in human breast cancer: Evidence suggesting that an elevated 
prostaglandin production is a marker of high metastatic potential for neoplastic 
cells. J Natl Cancer Inst, 64: 1061-1070, 1980. 
77. Pradono, P., Tazawa, R., Maemondo, M., Tanaka, M., Usui, K., Saijo, Y., 
Hagiwara, K., and Nukiwa, T. Gene transfer of thromboxane A(2) synthase and 
prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor 
growth. Cancer Res, 62: 63-66, 2002. 
78. Taub, M., Chuman, L., Saier, M. H., Jr., and Sato, G. Growth of Madin-Darby 
canine kidney epithelial cell (MDCK) line in hormone-supplemented, serum-free 
medium. Proc Natl Acad Sci U S A, 76: 3338-3342, 1979. 
79. Taub, M., Saier, M. H., Jr., Chuman, L., and Hiller, S. Loss of the PGE1 
requirement for MDCK cell growth associated with a defect in cyclic AMP 
phosphodiesterase. J Cell Physiol, 114: 153-161, 1983. 
80. Hansen-Petrik, M. B., McEntee, M. F., Jull, B., Shi, H., Zemel, M. B., and 
Whelan, J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-
inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res, 62: 403-
408, 2002. 
81. Wang, D., Wang, H., Shi, Q., Katkuri, S., Walhi, W., Desvergne, B., Das, S. K., 
Dey, S. K., and DuBois, R. N. Prostaglandin E(2) promotes colorectal adenoma 
growth via transactivation of the nuclear peroxisome proliferator-activated 
receptor delta. Cancer Cell, 6: 285-295, 2004. 
82. Hull, M. A., Ko, S. C., and Hawcroft, G. Prostaglandin EP receptors: targets for 
treatment and prevention of colorectal cancer? Mol Cancer Ther, 3: 1031-1039, 
2004. 
83. Pugh, S. and Thomas, G. A. Patients with adenomatous polyps and carcinomas 
have increased colonic mucosal prostaglandin E2. Gut, 35: 675-678, 1994. 
84. Giardiello, F. M., Casero, R. A., Jr., Hamilton, S. R., Hylind, L. M., Trimbath, J. 
D., Geiman, D. E., Judge, K. R., Hubbard, W., Offerhaus, G. J., and Yang, V. W. 
Prostanoids, ornithine decarboxylase, and polyamines in primary 
chemoprevention of familial adenomatous polyposis. Gastroenterology, 126: 425-
431, 2004. 
85. Ben-Av, P., Crofford, L. J., Wilder, R. L., and Hla, T. Induction of vascular 
endothelial growth factor expression in synovial fibroblasts by prostaglandin E 
95 
and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS 
Lett, 372: 83-87, 1995. 
86. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D., and DuBois, R. N. 
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human 
colon cancer cells. Cancer Res, 58: 362-366, 1998. 
87. Sheng, H., Shao, J., Washington, M. K., and DuBois, R. N. Prostaglandin E2 
increases growth and motility of colorectal carcinoma cells. J Biol Chem, 276: 
18075-18081, 2001. 
88. Balch, C. M., Dougherty, P. A., Cloud, G. A., and Tilden, A. B. Prostaglandin E2-
mediated suppression of cellular immunity in colon cancer patients. Surgery, 95: 
71-77, 1984. 
89. Fukuda, R., Kelly, B., and Semenza, G. L. Vascular endothelial growth factor 
gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by 
hypoxia-inducible factor 1. Cancer Res, 63: 2330-2334, 2003. 
90. Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., 
Kronenberg, M., Miller, P. W., Portanova, J., Lee, J. C., and Dubinett, S. M. 
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering 
the balance of IL-10 and IL-12 synthesis. J Immunol, 164: 361-370, 2000. 
91. Coggins, K. G., Latour, A., Nguyen, M. S., Audoly, L., Coffman, T. M., and 
Koller, B. H. Metabolism of PGE2 by prostaglandin dehydrogenase is essential 
for remodeling the ductus arteriosus. Nat Med, 8: 91-92, 2002. 
92. Backlund, M. G., Mann, J. R., Holla, V. R., Buchanan, F. G., Tai, H. H., Musiek, 
E. S., Milne, G. L., Katkuri, S., and DuBois, R. N. 15-Hydroxyprostaglandin 
dehydrogenase is down-regulated in colorectal cancer. J Biol Chem, 280: 3217-
3223, 2005. 
93. Ding, Y., Tong, M., Liu, S., Moscow, J. A., and Tai, H. H. NAD+-linked 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor 
in lung cancer. Carcinogenesis, 26: 65-72, 2005. 
94. Gee, J. R., Montoya, R. G., Khaled, H. M., Sabichi, A. L., and Grossman, H. B. 
Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and 
squamous cell carcinoma of the bladder. Urol Oncol, 21: 266-270, 2003. 
95. Yan, M., Rerko, R. M., Platzer, P., Dawson, D., Willis, J., Tong, M., Lawrence, 
E., Lutterbaugh, J., Lu, S., Willson, J. K., Luo, G., Hensold, J., Tai, H. H., 
Wilson, K., and Markowitz, S. D. 15-Hydroxyprostaglandin dehydrogenase, a 
COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human 
gastrointestinal cancers. Proc Natl Acad Sci U S A, 101: 17468-17473, 2004. 
96. Mann, J. R., Backlund, M. G., Buchanan, F. G., Daikoku, T., Holla, V. R., 
Rosenberg, D. W., Dey, S. K., and DuBois, R. N. Repression of prostaglandin 
dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 
and promotes cancer progression. Cancer Res, 66: 6649-6656, 2006. 
97. Breyer, M. D. and Breyer, R. M. Prostaglandin E receptors and the kidney. Am J 
Physiol Renal Physiol, 279: F12-23, 2000. 
98. Narumiya, S., Sugimoto, Y., and Ushikubi, F. Prostanoid receptors: structures, 
properties, and functions. Physiol Rev, 79: 1193-1226, 1999. 
99. Schuster, V. L. Molecular mechanisms of prostaglandin transport. Annu Rev 
Physiol, 60: 221-242, 1998. 
96 
100. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., 
Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N. M., Belley, M., Gallant, 
M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N., and 
Metters, K. M. The utilization of recombinant prostanoid receptors to determine 
the affinities and selectivities of prostaglandins and related analogs. Biochim 
Biophys Acta, 1483: 285-293, 2000. 
101. Bhattacharya, M., Peri, K. G., Almazan, G., Ribeiro-da-Silva, A., Shichi, H., 
Durocher, Y., Abramovitz, M., Hou, X., Varma, D. R., and Chemtob, S. Nuclear 
localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A, 95: 15792-
15797, 1998. 
102. Bhattacharya, M., Peri, K., Ribeiro-da-Silva, A., Almazan, G., Shichi, H., Hou, 
X., Varma, D. R., and Chemtob, S. Localization of functional prostaglandin E2 
receptors EP3 and EP4 in the nuclear envelope. J Biol Chem, 274: 15719-15724, 
1999. 
103. Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., 
Narumiya, S., and Ichikawa, A. Cloning and expression of a cDNA for mouse 
prostaglandin E receptor EP2 subtype. J Biol Chem, 268: 7759-7762, 1993. 
104. Katsuyama, M., Nishigaki, N., Sugimoto, Y., Morimoto, K., Negishi, M., 
Narumiya, S., and Ichikawa, A. The mouse prostaglandin E receptor EP2 subtype: 
cloning, expression, and northern blot analysis. FEBS Lett, 372: 151-156, 1995. 
105. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A., and 
Narumiya, S. Cloning and expression of a cDNA for mouse prostaglandin E 
receptor EP3 subtype. J Biol Chem, 267: 6463-6466, 1992. 
106. Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., 
Narumiya, S., and Ichikawa, A. Cloning and expression of cDNA for a mouse 
EP1 subtype of prostaglandin E receptor. J Biol Chem, 268: 20175-20178, 1993. 
107. Toh, H., Ichikawa, A., and Narumiya, S. Molecular evolution of receptors for 
eicosanoids. FEBS Lett, 361: 17-21, 1995. 
108. Kennedy, I., Coleman, R. A., Humphrey, P. P., Levy, G. P., and Lumley, P. 
Studies on the characterisation of prostanoid receptors: a proposed classification. 
Prostaglandins, 24: 667-689, 1982. 
109. Coleman, R. A., Kennedy, I., and Sheldrick, R. L. New evidence with selective 
agonists and antagonists for the subclassification of PGE2-sensitive (EP) 
receptors. Adv Prostaglandin Thromboxane Leukot Res, 17A: 467-470, 1987. 
110. Coleman, R. A., Smith, W. L., and Narumiya, S. International Union of 
Pharmacology classification of prostanoid receptors: properties, distribution, and 
structure of the receptors and their subtypes. Pharmacol Rev, 46: 205-229, 1994. 
111. Funk, C. D., Furci, L., FitzGerald, G. A., Grygorczyk, R., Rochette, C., Bayne, M. 
A., Abramovitz, M., Adam, M., and Metters, K. M. Cloning and expression of a 
cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem, 268: 
26767-26772, 1993. 
112. Bunce, K. T. and Spraggs, C. F. Prostanoid stimulation of anion secretion in 
guinea-pig gastric and ileal mucosa is mediated by different receptors. Br J 
Pharmacol, 101: 889-895, 1990. 
113. Regan, J. W., Bailey, T. J., Pepperl, D. J., Pierce, K. L., Bogardus, A. M., 
Donello, J. E., Fairbairn, C. E., Kedzie, K. M., Woodward, D. F., and Gil, D. W. 
97 
Cloning of a novel human prostaglandin receptor with characteristics of the 
pharmacologically defined EP2 subtype. Mol Pharmacol, 46: 213-220, 1994. 
114. Nakao, A., Allen, M. L., Sonnenburg, W. K., and Smith, W. L. Regulation of 
cAMP metabolism by PGE2 in cortical and medullary thick ascending limb of 
Henle's loop. Am J Physiol, 256: C652-657, 1989. 
115. Fujino, H., Xu, W., and Regan, J. W. Prostaglandin E2 induced functional 
expression of early growth response factor-1 by EP4, but not EP2, prostanoid 
receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated 
kinases. J Biol Chem, 278: 12151-12156, 2003. 
116. Regan, J. W. EP(2) and EP(4) prostanoid receptor signaling. Life Sci, 74: 143-
153, 2003. 
117. Sonnenburg, W. K., Zhu, J. H., and Smith, W. L. A prostaglandin E receptor 
coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in 
rabbit cortical collecting tubule cells. J Biol Chem, 265: 8479-8483, 1990. 
118. Aoki, J., Katoh, H., Yasui, H., Yamaguchi, Y., Nakamura, K., Hasegawa, H., 
Ichikawa, A., and Negishi, M. Signal transduction pathway regulating 
prostaglandin EP3 receptor-induced neurite retraction: requirement for two 
different tyrosine kinases. Biochem J, 340 ( Pt 2): 365-369, 1999. 
119. Katoh, H., Negishi, M., and Ichikawa, A. Prostaglandin E receptor EP3 subtype 
induces neurite retraction via small GTPase Rho. J Biol Chem, 271: 29780-
29784, 1996. 
120. Hasegawa, H., Negishi, M., Katoh, H., and Ichikawa, A. Two isoforms of 
prostaglandin EP3 receptor exhibiting constitutive activity and agonist-dependent 
activity in Rho-mediated stress fiber formation. Biochem Biophys Res Commun, 
234: 631-636, 1997. 
121. Breyer, R. M., Bagdassarian, C. K., Myers, S. A., and Breyer, M. D. Prostanoid 
receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol, 41: 661-690, 
2001. 
122. Breyer, R. M., Davis, L. S., Nian, C., Redha, R., Stillman, B., Jacobson, H. R., 
and Breyer, M. D. Cloning and expression of the rabbit prostaglandin EP4 
receptor. Am J Physiol, 270: F485-493, 1996. 
123. Morimoto, K., Sugimoto, Y., Katsuyama, M., Oida, H., Tsuboi, K., Kishi, K., 
Kinoshita, Y., Negishi, M., Chiba, T., Narumiya, S., and Ichikawa, A. Cellular 
localization of mRNAs for prostaglandin E receptor subtypes in mouse 
gastrointestinal tract. Am J Physiol, 272: G681-687, 1997. 
124. Bukhave, K. and Rask-Madsen, J. Saturation kinetics applied to in vitro effects of 
low prostaglandin E2 and F 2 alpha concentrations on ion transport across human 
jejunal mucosa. Gastroenterology, 78: 32-42, 1980. 
125. Sugimoto, Y., Shigemoto, R., Namba, T., Negishi, M., Mizuno, N., Narumiya, S., 
and Ichikawa, A. Distribution of the messenger RNA for the prostaglandin E 
receptor subtype EP3 in the mouse nervous system. Neuroscience, 62: 919-928, 
1994. 
126. Kunikata, T., Yamane, H., Segi, E., Matsuoka, T., Sugimoto, Y., Tanaka, S., 
Tanaka, H., Nagai, H., Ichikawa, A., and Narumiya, S. Suppression of allergic 
inflammation by the prostaglandin E receptor subtype EP3. Nat Immunol, 6: 524-
531, 2005. 
98 
127. Kennedy, C. R., Xiong, H., Rahal, S., Vanderluit, J., Slack, R. S., Zhang, Y., 
Guan, Y., Breyer, M. D., and Hebert, R. L. Urine concentrating defect in 
prostaglandin EP1-deficient mice. Am J Physiol Renal Physiol, 292: F868-875, 
2007. 
128. Stock, J. L., Shinjo, K., Burkhardt, J., Roach, M., Taniguchi, K., Ishikawa, T., 
Kim, H. S., Flannery, P. J., Coffman, T. M., McNeish, J. D., and Audoly, L. P. 
The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood 
pressure. J Clin Invest, 107: 325-331, 2001. 
129. Hizaki, H., Segi, E., Sugimoto, Y., Hirose, M., Saji, T., Ushikubi, F., Matsuoka, 
T., Noda, Y., Tanaka, T., Yoshida, N., Narumiya, S., and Ichikawa, A. Abortive 
expansion of the cumulus and impaired fertility in mice lacking the prostaglandin 
E receptor subtype EP(2). Proc Natl Acad Sci U S A, 96: 10501-10506, 1999. 
130. Tilley, S. L., Audoly, L. P., Hicks, E. H., Kim, H. S., Flannery, P. J., Coffman, T. 
M., and Koller, B. H. Reproductive failure and reduced blood pressure in mice 
lacking the EP2 prostaglandin E2 receptor. J Clin Invest, 103: 1539-1545, 1999. 
131. Reinold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., Pahl, 
A., Brune, K., Narumiya, S., Muller, U., and Zeilhofer, H. U. Spinal inflammatory 
hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin 
Invest, 115: 673-679, 2005. 
132. Kobayashi, T. and Narumiya, S. Function of prostanoid receptors: studies on 
knockout mice. Prostaglandins Other Lipid Mediat, 68-69: 557-573, 2002. 
133. Sakuma, Y., Tanaka, K., Suda, M., Yasoda, A., Natsui, K., Tanaka, I., Ushikubi, 
F., Narumiya, S., Segi, E., Sugimoto, Y., Ichikawa, A., and Nakao, K. Crucial 
involvement of the EP4 subtype of prostaglandin E receptor in osteoclast 
formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner 
Res, 15: 218-227, 2000. 
134. Miyaura, C., Inada, M., Suzawa, T., Sugimoto, Y., Ushikubi, F., Ichikawa, A., 
Narumiya, S., and Suda, T. Impaired bone resorption to prostaglandin E2 in 
prostaglandin E receptor EP4-knockout mice. J Biol Chem, 275: 19819-19823, 
2000. 
135. Li, X., Okada, Y., Pilbeam, C. C., Lorenzo, J. A., Kennedy, C. R., Breyer, R. M., 
and Raisz, L. G. Knockout of the murine prostaglandin EP2 receptor impairs 
osteoclastogenesis in vitro. Endocrinology, 141: 2054-2061, 2000. 
136. Segi, E., Sugimoto, Y., Yamasaki, A., Aze, Y., Oida, H., Nishimura, T., Murata, 
T., Matsuoka, T., Ushikubi, F., Hirose, M., Tanaka, T., Yoshida, N., Narumiya, 
S., and Ichikawa, A. Patent ductus arteriosus and neonatal death in prostaglandin 
receptor EP4-deficient mice. Biochem Biophys Res Commun, 246: 7-12, 1998. 
137. Nguyen, M., Camenisch, T., Snouwaert, J. N., Hicks, E., Coffman, T. M., 
Anderson, P. A., Malouf, N. N., and Koller, B. H. The prostaglandin receptor EP4 
triggers remodelling of the cardiovascular system at birth. Nature, 390: 78-81, 
1997. 
138. Kabashima, K., Sakata, D., Nagamachi, M., Miyachi, Y., Inaba, K., and 
Narumiya, S. Prostaglandin E2-EP4 signaling initiates skin immune responses by 
promoting migration and maturation of Langerhans cells. Nat Med, 9: 744-749, 
2003. 
99 
139. Kabashima, K., Saji, T., Murata, T., Nagamachi, M., Matsuoka, T., Segi, E., 
Tsuboi, K., Sugimoto, Y., Kobayashi, T., Miyachi, Y., Ichikawa, A., and 
Narumiya, S. The prostaglandin receptor EP4 suppresses colitis, mucosal damage 
and CD4 cell activation in the gut. J Clin Invest, 109: 883-893, 2002. 
140. Ushikubi, F., Segi, E., Sugimoto, Y., Murata, T., Matsuoka, T., Kobayashi, T., 
Hizaki, H., Tuboi, K., Katsuyama, M., Ichikawa, A., Tanaka, T., Yoshida, N., and 
Narumiya, S. Impaired febrile response in mice lacking the prostaglandin E 
receptor subtype EP3. Nature, 395: 281-284, 1998. 
141. Ueno, A., Matsumoto, H., Naraba, H., Ikeda, Y., Ushikubi, F., Matsuoka, T., 
Narumiya, S., Sugimoto, Y., Ichikawa, A., and Oh-ishi, S. Major roles of 
prostanoid receptors IP and EP(3) in endotoxin-induced enhancement of pain 
perception. Biochem Pharmacol, 62: 157-160, 2001. 
142. Takeuchi, K., Ukawa, H., Kato, S., Furukawa, O., Araki, H., Sugimoto, Y., 
Ichikawa, A., Ushikubi, F., and Narumiya, S. Impaired duodenal bicarbonate 
secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype 
EP(3). Gastroenterology, 117: 1128-1135, 1999. 
143. Sanchez-Alavez, M., Klein, I., Brownell, S. E., Tabarean, I. V., Davis, C. N., 
Conti, B., and Bartfai, T. Night eating and obesity in the EP3R-deficient mouse. 
Proc Natl Acad Sci U S A, 104: 3009-3014, 2007. 
144. Belley, A. and Chadee, K. Prostaglandin E(2) stimulates rat and human colonic 
mucin exocytosis via the EP(4) receptor. Gastroenterology, 117: 1352-1362, 
1999. 
145. Takafuji, V., Cosme, R., Lublin, D., Lynch, K., and Roche, J. K. Prostanoid 
receptors in intestinal epithelium: selective expression, function, and change with 
inflammation. Prostaglandins Leukot Essent Fatty Acids, 63: 223-235, 2000. 
146. Ma, X., Kundu, N., Rifat, S., Walser, T., and Fulton, A. M. Prostaglandin E 
receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res, 66: 2923-
2927, 2006. 
147. Chang, S. H., Ai, Y., Breyer, R. M., Lane, T. F., and Hla, T. The prostaglandin E2 
receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. 
Cancer Res, 65: 4496-4499, 2005. 
148. Kawamori, T., Uchiya, N., Nakatsugi, S., Watanabe, K., Ohuchida, S., 
Yamamoto, H., Maruyama, T., Kondo, K., Sugimura, T., and Wakabayashi, K. 
Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor 
EP(1) antagonist, on breast cancer development. Carcinogenesis, 22: 2001-2004, 
2001. 
149. An, K. P., Athar, M., Tang, X., Katiyar, S. K., Russo, J., Beech, J., Aszterbaum, 
M., Kopelovich, L., Epstein, E. H., Jr., Mukhtar, H., and Bickers, D. R. 
Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: 
implications for therapeutic approaches. Photochem Photobiol, 76: 73-80, 2002. 
150. Sung, Y. M., He, G., and Fischer, S. M. Lack of expression of the EP2 but not 
EP3 receptor for prostaglandin E2 results in suppression of skin tumor 
development. Cancer Res, 65: 9304-9311, 2005. 
151. Brouxhon, S., Konger, R. L., VanBuskirk, J., Sheu, T. J., Ryan, J., Erdle, B., 
Almudevar, A., Breyer, R. M., Scott, G., and Pentland, A. P. Deletion of 
100 
prostaglandin E2 EP2 receptor protects against ultraviolet-induced carcinogenesis, 
but increases tumor aggressiveness. J Invest Dermatol, 127: 439-446, 2007. 
152. Tober, K. L., Wilgus, T. A., Kusewitt, D. F., Thomas-Ahner, J. M., Maruyama, 
T., and Oberyszyn, T. M. Importance of the EP(1) receptor in cutaneous UVB-
induced inflammation and tumor development. J Invest Dermatol, 126: 205-211, 
2006. 
153. Kawamori, T., Uchiya, N., Sugimura, T., and Wakabayashi, K. Enhancement of 
colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis, 24: 
985-990, 2003. 
154. Mutoh, M., Watanabe, K., Kitamura, T., Shoji, Y., Takahashi, M., Kawamori, T., 
Tani, K., Kobayashi, M., Maruyama, T., Kobayashi, K., Ohuchida, S., Sugimoto, 
Y., Narumiya, S., Sugimura, T., and Wakabayashi, K. Involvement of 
prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res, 62: 
28-32, 2002. 
155. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, 
H., Maruyama, T., Kondo, K., Ushikubi, F., Narumiya, S., Sugimura, T., and 
Wakabayashi, K. Role of the prostaglandin E receptor subtype EP1 in colon 
carcinogenesis. Cancer Res, 59: 5093-5096, 1999. 
156. Sonoshita, M., Takaku, K., Sasaki, N., Sugimoto, Y., Ushikubi, F., Narumiya, S., 
Oshima, M., and Taketo, M. M. Acceleration of intestinal polyposis through 
prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med, 7: 1048-
1051, 2001. 
157. Sugimoto, Y., Negishi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., 
Hirata, M., Narumiya, S., and Ichikawa, A. Two isoforms of the EP3 receptor 
with different carboxyl-terminal domains. Identical ligand binding properties and 
different coupling properties with Gi proteins. J Biol Chem, 268: 2712-2718, 
1993. 
158. Namba, T., Sugimoto, Y., Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, 
S., Ichikawa, A., and Narumiya, S. Alternative splicing of C-terminal tail of 
prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature, 
365: 166-170, 1993. 
159. Irie, A., Sugimoto, Y., Namba, T., Harazono, A., Honda, A., Watabe, A., Negishi, 
M., Narumiya, S., and Ichikawa, A. Third isoform of the prostaglandin-E-receptor 
EP3 subtype with different C-terminal tail coupling to both stimulation and 
inhibition of adenylate cyclase. Eur J Biochem, 217: 313-318, 1993. 
160. Breyer, R. M., Emeson, R. B., Tarng, J. L., Breyer, M. D., Davis, L. S., 
Abromson, R. M., and Ferrenbach, S. M. Alternative splicing generates multiple 
isoforms of a rabbit prostaglandin E2 receptor. J Biol Chem, 269: 6163-6169, 
1994. 
161. Audoly, L. P., Ma, L., Feoktistov, I., de Foe, S. K., Breyer, M. D., and Breyer, R. 
M. Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response 
element-mediated gene transcription. J Pharmacol Exp Ther, 289: 140-148, 1999. 
162. Bilson, H. A., Mitchell, D. L., and Ashby, B. Human prostaglandin EP3 receptor 
isoforms show different agonist-induced internalization patterns. FEBS Lett, 572: 
271-275, 2004. 
101 
163. Negishi, M., Hasegawa, H., and Ichikawa, A. Prostaglandin E receptor 
EP3gamma isoform, with mostly full constitutive Gi activity and agonist-
dependent Gs activity. FEBS Lett, 386: 165-168, 1996. 
164. Hasegawa, H., Negishi, M., and Ichikawa, A. Two isoforms of the prostaglandin 
E receptor EP3 subtype different in agonist-independent constitutive activity. J 
Biol Chem, 271: 1857-1860, 1996. 
165. Shoji, Y., Takahashi, M., Kitamura, T., Watanabe, K., Kawamori, T., Maruyama, 
T., Sugimoto, Y., Negishi, M., Narumiya, S., Sugimura, T., and Wakabayashi, K. 
Downregulation of prostaglandin E receptor subtype EP3 during colon cancer 
development. Gut, 53: 1151-1158, 2004. 
166. Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., 
Lane, T. F., and Hla, T. Role of prostaglandin E2-dependent angiogenic switch in 
cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A, 
101: 591-596, 2004. 
167. Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., 
Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., Murata, T., Yoshimura, H., 
Narumiya, S., and Majima, M. Host prostaglandin E(2)-EP3 signaling regulates 
tumor-associated angiogenesis and tumor growth. J Exp Med, 197: 221-232, 
2003. 
168. Pozzi, A., Yan, X., Macias-Perez, I., Wei, S., Hata, A. N., Breyer, R. M., Morrow, 
J. D., and Capdevila, J. H. Colon carcinoma cell growth is associated with 
prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem, 279: 29797-
29804, 2004. 
169. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J., 
Beauchamp, R. D., and DuBois, R. N. Inhibition of human colon cancer cell 
growth by selective inhibition of cyclooxygenase-2. J Clin Invest, 99: 2254-2259, 
1997. 
170. Irie, A., Segi, E., Sugimoto, Y., Ichikawa, A., and Negishi, M. Mouse 
prostaglandin E receptor EP3 subtype mediates calcium signals via Gi in cDNA-
transfected Chinese hamster ovary cells. Biochem Biophys Res Commun, 204: 
303-309, 1994. 
171. Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., and Gutkind, J. 
S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-
catenin signaling axis. Science, 310: 1504-1510, 2005. 
172. Kanda, N., Koike, S., and Watanabe, S. Prostaglandin E2 enhances neurotrophin-
4 production via EP3 receptor in human keratinocytes. J Pharmacol Exp Ther, 
315: 796-804, 2005. 
173. Kotani, M., Tanaka, I., Ogawa, Y., Suganami, T., Matsumoto, T., Muro, S., 
Yamamoto, Y., Sugawara, A., Yoshimasa, Y., Sagawa, N., Narumiya, S., and 
Nakao, K. Multiple signal transduction pathways through two prostaglandin E 
receptor EP3 subtype isoforms expressed in human uterus. J Clin Endocrinol 
Metab, 85: 4315-4322, 2000. 
174. Katoh, H., Aoki, J., Yamaguchi, Y., Kitano, Y., Ichikawa, A., and Negishi, M. 
Constitutively active Galpha12, Galpha13, and Galphaq induce Rho-dependent 
neurite retraction through different signaling pathways. J Biol Chem, 273: 28700-
28707, 1998. 
102 
175. Scherpereel, A., Gentina, T., Grigoriu, B., Senechal, S., Janin, A., Tsicopoulos, 
A., Plenat, F., Bechard, D., Tonnel, A. B., and Lassalle, P. Overexpression of 
endocan induces tumor formation. Cancer Res, 63: 6084-6089, 2003. 
176. Falcetti, E., Flavell, D. M., Staels, B., Tinker, A., Haworth, S. G., and Clapp, L. 
H. IP receptor-dependent activation of PPARgamma by stable prostacyclin 
analogues. Biochem Biophys Res Commun, 360: 821-827, 2007. 
177. Sasaki, M., Sukegawa, J., Miyosawa, K., Yanagisawa, T., Ohkubo, S., and 
Nakahata, N. Low expression of cell-surface thromboxane A2 receptor beta-
isoform through the negative regulation of its membrane traffic by proteasomes. 
Prostaglandins Other Lipid Mediat, 83: 237-249, 2007. 
178. Wilson, R. J. and Giles, H. Piglet saphenous vein contains multiple relaxatory 
prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J 
Pharmacol, 144: 405-415, 2005. 
179. Chen, X. B. and Regan, J. W. Activation of the human FP prostanoid receptor 
disrupts mitosis progression and generates aneuploidy and polyploidy. Cell Mol 
Life Sci, 63: 112-121, 2006. 
180. Negishi, M., Sugimoto, Y., Irie, A., Narumiya, S., and Ichikawa, A. Two isoforms 
of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains 
determine sensitivity to agonist-induced desensitization. J Biol Chem, 268: 9517-
9521, 1993. 
181. Hasegawa, H., Katoh, H., Yamaguchi, Y., Nakamura, K., Futakawa, S., and 
Negishi, M. Different membrane targeting of prostaglandin EP3 receptor isoforms 
dependent on their carboxy-terminal tail structures. FEBS Lett, 473: 76-80, 2000. 
182. Thompson, E. W., Newgreen, D. F., and Tarin, D. Carcinoma invasion and 
metastasis: a role for epithelial-mesenchymal transition? Cancer Res, 65: 5991-
5995; discussion 5995, 2005. 
183. Thiery, J. P. and Sleeman, J. P. Complex networks orchestrate epithelial-
mesenchymal transitions. Nat Rev Mol Cell Biol, 7: 131-142, 2006. 
184. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer, 2: 442-454, 2002. 
185. Savagner, P. Leaving the neighborhood: molecular mechanisms involved during 
epithelial-mesenchymal transition. Bioessays, 23: 912-923, 2001. 
186. Gupta, G. P. and Massague, J. Cancer metastasis: building a framework. Cell, 
127: 679-695, 2006. 
187. Riobo, N. A. and Manning, D. R. Receptors coupled to heterotrimeric G proteins 
of the G12 family. Trends Pharmacol Sci, 26: 146-154, 2005. 
188. Kozasa, T., Jiang, X., Hart, M. J., Sternweis, P. M., Singer, W. D., Gilman, A. G., 
Bollag, G., and Sternweis, P. C. p115 RhoGEF, a GTPase activating protein for 
Galpha12 and Galpha13. Science, 280: 2109-2111, 1998. 
189. Girkontaite, I., Missy, K., Sakk, V., Harenberg, A., Tedford, K., Potzel, T., 
Pfeffer, K., and Fischer, K. D. Lsc is required for marginal zone B cells, 
regulation of lymphocyte motility and immune responses. Nat Immunol, 2: 855-
862, 2001. 
190. Dorsam, R. T. and Gutkind, J. S. G-protein-coupled receptors and cancer. Nat 
Rev Cancer, 7: 79-94, 2007. 
103 
191. Wang, Q., Liu, M., Kozasa, T., Rothestein, J. D., Sternweis, P. C., and Neubig, R. 
R. Ribozyme- and siRNA-mediated suppression of RGS-containing RhoGEF 
proteins. Methods Enzymol, 389: 244-265, 2004. 
192. He, H., Pannequin, J., Tantiongco, J. P., Shulkes, A., and Baldwin, G. S. Glycine-
extended gastrin stimulates cell proliferation and migration through a Rho- and 
ROCK-dependent pathway, not a Rac/Cdc42-dependent pathway. Am J Physiol 
Gastrointest Liver Physiol, 289: G478-488, 2005. 
193. Van Aelst, L. and D'Souza-Schorey, C. Rho GTPases and signaling networks. 
Genes Dev, 11: 2295-2322, 1997. 
194. Vishnubhotla, R., Sun, S., Huq, J., Bulic, M., Ramesh, A., Guzman, G., Cho, M., 
and Glover, S. C. ROCK-II mediates colon cancer invasion via regulation of 
MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton 
imaging. Lab Invest, 87: 1149-1158, 2007. 
195. Nusrat, A., Giry, M., Turner, J. R., Colgan, S. P., Parkos, C. A., Carnes, D., 
Lemichez, E., Boquet, P., and Madara, J. L. Rho protein regulates tight junctions 
and perijunctional actin organization in polarized epithelia. Proc Natl Acad Sci U 
S A, 92: 10629-10633, 1995. 
196. Sahai, E. and Marshall, C. J. Differing modes of tumour cell invasion have 
distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat 
Cell Biol, 5: 711-719, 2003. 
197. Fukui, K., Tamura, S., Wada, A., Kamada, Y., Sawai, Y., Imanaka, K., Kudara, 
T., Shimomura, I., and Hayashi, N. Expression and prognostic role of RhoA 
GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol, 132: 627-633, 
2006. 
198. Nelson, P. J. and Daniel, T. O. Emerging targets: Molecular mechanisms of cell 
contact-mediated growth control. Kidney Int, 61: 99-105, 2002. 
199. Yamada, S. and Nelson, W. J. Localized zones of Rho and Rac activities drive 
initiation and expansion of epithelial cell-cell adhesion. J Cell Biol, 178: 517-527, 
2007. 
200. Jones, P. A. and Laird, P. W. Cancer epigenetics comes of age. Nat Genet, 21: 
163-167, 1999. 
201. Baylin, S. B. and Herman, J. G. DNA hypermethylation in tumorigenesis: 
epigenetics joins genetics. Trends Genet, 16: 168-174, 2000. 
 
 
